WO2020220086A1 - Immunosensor - Google Patents
Immunosensor Download PDFInfo
- Publication number
- WO2020220086A1 WO2020220086A1 PCT/AU2020/050430 AU2020050430W WO2020220086A1 WO 2020220086 A1 WO2020220086 A1 WO 2020220086A1 AU 2020050430 W AU2020050430 W AU 2020050430W WO 2020220086 A1 WO2020220086 A1 WO 2020220086A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cret
- pair
- component
- molecule
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims abstract description 353
- 108091007433 antigens Proteins 0.000 claims abstract description 353
- 102000036639 antigens Human genes 0.000 claims abstract description 353
- 238000000034 method Methods 0.000 claims abstract description 182
- 239000012491 analyte Substances 0.000 claims abstract description 150
- 238000003392 chemiluminescence resonance energy transfer Methods 0.000 claims description 412
- 239000000523 sample Substances 0.000 claims description 159
- 238000012546 transfer Methods 0.000 claims description 145
- 230000027455 binding Effects 0.000 claims description 107
- 239000005090 green fluorescent protein Substances 0.000 claims description 98
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 235000018102 proteins Nutrition 0.000 claims description 76
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 70
- 239000000758 substrate Substances 0.000 claims description 68
- 229920001184 polypeptide Polymers 0.000 claims description 66
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 54
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 54
- 108060001084 Luciferase Proteins 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 239000005089 Luciferase Substances 0.000 claims description 46
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 44
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 44
- -1 antibiotic Substances 0.000 claims description 39
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 38
- 235000018417 cysteine Nutrition 0.000 claims description 38
- 229920001223 polyethylene glycol Polymers 0.000 claims description 38
- 108091033319 polynucleotide Proteins 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 33
- 239000002157 polynucleotide Substances 0.000 claims description 33
- 239000002202 Polyethylene glycol Substances 0.000 claims description 32
- 230000009467 reduction Effects 0.000 claims description 32
- 108010052090 Renilla Luciferases Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 29
- 230000002829 reductive effect Effects 0.000 claims description 29
- 230000021615 conjugation Effects 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 22
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical group OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 18
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 16
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 15
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 15
- 239000013566 allergen Substances 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 238000002165 resonance energy transfer Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 11
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 108010021843 fluorescent protein 583 Proteins 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 108090000331 Firefly luciferases Proteins 0.000 claims description 8
- 108010053210 Phycocyanin Proteins 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- HTBLMRUZSCCOLL-UHFFFAOYSA-N 8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3-ol Chemical compound OC1=C(CC2=CC=CO2)N=C2N1C=C(N=C2CC1=CC=CC=C1)C1=CC=CC=C1 HTBLMRUZSCCOLL-UHFFFAOYSA-N 0.000 claims description 7
- 239000002359 drug metabolite Substances 0.000 claims description 7
- 241000700108 Ctenophora <comb jellyfish phylum> Species 0.000 claims description 6
- 241000963438 Gaussia <copepod> Species 0.000 claims description 6
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 claims description 4
- 108010000239 Aequorin Proteins 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 4
- 108090000363 Bacterial Luciferases Proteins 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 210000002500 microbody Anatomy 0.000 claims description 4
- 239000011031 topaz Substances 0.000 claims description 4
- 229910052853 topaz Inorganic materials 0.000 claims description 4
- 101100068321 Aequorea victoria GFP gene Proteins 0.000 claims description 3
- 241000059559 Agriotes sordidus Species 0.000 claims description 3
- 241000402204 Arachnocampa Species 0.000 claims description 3
- 241000131894 Lampyris noctiluca Species 0.000 claims description 3
- 241000522587 Oplophorus gracilirostris Species 0.000 claims description 3
- 241000242739 Renilla Species 0.000 claims description 3
- 241001136903 Rhagoletis pomonella Species 0.000 claims description 3
- 108060006184 phycobiliprotein Proteins 0.000 claims description 3
- 108010054624 red fluorescent protein Proteins 0.000 claims description 3
- 229910052594 sapphire Inorganic materials 0.000 claims description 3
- 239000010980 sapphire Substances 0.000 claims description 3
- 108010004729 Phycoerythrin Proteins 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 description 158
- 210000004027 cell Anatomy 0.000 description 66
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 60
- 239000002953 phosphate buffered saline Substances 0.000 description 52
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 47
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 41
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 38
- 108010020195 FLAG peptide Proteins 0.000 description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 35
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 33
- 238000003556 assay Methods 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 239000002096 quantum dot Substances 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 20
- 125000000524 functional group Chemical group 0.000 description 20
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 19
- 238000002523 gelfiltration Methods 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 239000011534 wash buffer Substances 0.000 description 16
- 239000004472 Lysine Substances 0.000 description 15
- 238000011033 desalting Methods 0.000 description 15
- 239000000975 dye Substances 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 238000004020 luminiscence type Methods 0.000 description 15
- 235000018977 lysine Nutrition 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000004365 Protease Substances 0.000 description 13
- 238000010828 elution Methods 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 239000012505 Superdex™ Substances 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 150000001720 carbohydrates Chemical group 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 108010076818 TEV protease Proteins 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical class C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 9
- 229960001325 triclocarban Drugs 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 238000001742 protein purification Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- KOUZWQLNUJWNIA-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=NC=CC=C1C(N)=O KOUZWQLNUJWNIA-UHFFFAOYSA-N 0.000 description 7
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 7
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical group NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 7
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 102000034287 fluorescent proteins Human genes 0.000 description 7
- 108091006047 fluorescent proteins Proteins 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 229940127121 immunoconjugate Drugs 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 7
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 7
- 239000004065 semiconductor Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical group NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108090000526 Papain Proteins 0.000 description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000013626 chemical specie Substances 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 108010033706 glycylserine Proteins 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940055729 papain Drugs 0.000 description 6
- 235000019834 papain Nutrition 0.000 description 6
- 229920001515 polyalkylene glycol Polymers 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 5
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 description 5
- 101000879203 Caenorhabditis elegans Small ubiquitin-related modifier Proteins 0.000 description 5
- 241000238557 Decapoda Species 0.000 description 5
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 5
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 241000723792 Tobacco etch virus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 5
- 239000011615 dehydroascorbic acid Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000238366 Cephalopoda Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 235000014571 nuts Nutrition 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229910052761 rare earth metal Inorganic materials 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000238421 Arthropoda Species 0.000 description 3
- 229910004613 CdTe Inorganic materials 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000672609 Escherichia coli BL21 Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000242743 Renilla reniformis Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 150000004775 coumarins Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000004186 food analysis Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000009149 molecular binding Effects 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000006862 quantum yield reaction Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FIPPKBXQENOBSN-UHFFFAOYSA-N (dimethylhydrazinylidene)sulfamic acid Chemical compound CN(C)N=NS(O)(=O)=O FIPPKBXQENOBSN-UHFFFAOYSA-N 0.000 description 2
- AYDAHOIUHVUJHQ-UHFFFAOYSA-N 1-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)pyrrole-2,5-dione Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2N1C(=O)C=CC1=O AYDAHOIUHVUJHQ-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700686 Chaetognatha Species 0.000 description 2
- 241000243321 Cnidaria Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 241000239250 Copepoda Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- 229920000877 Melamine resin Polymers 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000254064 Photinus pyralis Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 241000255985 Trichoplusia Species 0.000 description 2
- 229910007709 ZnTe Inorganic materials 0.000 description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000005262 alkoxyamine group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- VVFZXPZWVJMYPX-UHFFFAOYSA-N dbco-peg4--maleimide Chemical compound C1C2=CC=CC=C2C#CC2=CC=CC=C2N1C(=O)CCNC(=O)CCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O VVFZXPZWVJMYPX-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- QUHVVVWAQMRCSJ-IXXPHHLHSA-N dinoflagellate luciferin Chemical compound N1C(CC2=C(C=3C(=O)CC(/C=3N2)=C/2[C@H]([C@H](C)[C@H](N\2)C(O)=O)CCC(O)=O)C)=C(CC)C(C)=C1CC1NC(=O)C(C)=C1C=C QUHVVVWAQMRCSJ-IXXPHHLHSA-N 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 125000005179 haloacetyl group Chemical group 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical group NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- QAVHLDCADYZYKN-UHFFFAOYSA-N methyl 3-(4-aminophenyl)sulfanylpropanoate Chemical compound COC(=O)CCSC1=CC=C(N)C=C1 QAVHLDCADYZYKN-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940031826 phenolate Drugs 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940043267 rhodamine b Drugs 0.000 description 2
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VQTBINYMFPKLQD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(3-hydroxy-6-oxoxanthen-9-yl)benzoate Chemical compound C=12C=CC(=O)C=C2OC2=CC(O)=CC=C2C=1C1=CC=CC=C1C(=O)ON1C(=O)CCC1=O VQTBINYMFPKLQD-UHFFFAOYSA-N 0.000 description 1
- ILKQVTIMOGNSAS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(7-amino-4-methyl-2-oxochromen-3-yl)acetate Chemical compound O=C1OC=2C=C(N)C=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O ILKQVTIMOGNSAS-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 description 1
- NNWQLZWAZSJGLY-VKHMYHEASA-N (2s)-2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)[C@@H](N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-VKHMYHEASA-N 0.000 description 1
- ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- ISNKSXRJJVWFIL-UHFFFAOYSA-N (sulfonylamino)amine Chemical compound NN=S(=O)=O ISNKSXRJJVWFIL-UHFFFAOYSA-N 0.000 description 1
- SGSVWAYHEWEQET-SCRDCRAPSA-N 1,5-dihydroriboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2NC2=C1NC(=O)NC2=O SGSVWAYHEWEQET-SCRDCRAPSA-N 0.000 description 1
- DTMMZESZHTZRSO-UHFFFAOYSA-N 1-[(3-acetyloxy-4-methyl-2-oxochromen-7-yl)amino]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound C1=C2OC(=O)C(OC(=O)C)=C(C)C2=CC=C1NN1C(=O)CC(S(O)(=O)=O)C1=O DTMMZESZHTZRSO-UHFFFAOYSA-N 0.000 description 1
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- MGTUVUVRFJVHAL-UHFFFAOYSA-N 2,8-dibenzyl-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-ol Chemical class Oc1c(Cc2ccccc2)nc2c(Cc3ccccc3)nc(cn12)-c1ccc(O)cc1 MGTUVUVRFJVHAL-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- IEXKUCOGQITOPO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEXKUCOGQITOPO-UHFFFAOYSA-N 0.000 description 1
- AVNJFDTZJJNPKF-ZDUSSCGKSA-N 2-[3-[2-[(2S)-butan-2-yl]-3-hydroxy-6-(1H-indol-3-yl)imidazo[1,2-a]pyrazin-8-yl]propyl]guanidine Chemical compound CC[C@H](C)c1nc2c(CCCNC(N)=[NH2+])nc(cn2c1[O-])-c1c[nH]c2ccccc12 AVNJFDTZJJNPKF-ZDUSSCGKSA-N 0.000 description 1
- SCGJGNWMYSYORS-UHFFFAOYSA-N 2-azaniumylhex-5-ynoate Chemical compound OC(=O)C(N)CCC#C SCGJGNWMYSYORS-UHFFFAOYSA-N 0.000 description 1
- BZRBMCOFGBMNEN-UHFFFAOYSA-N 2-benzoylprop-2-enamide Chemical compound NC(=O)C(=C)C(=O)C1=CC=CC=C1 BZRBMCOFGBMNEN-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 101710112984 20 kDa protein Proteins 0.000 description 1
- MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical class ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- KNFQJMQMVDKTPU-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid Chemical compound C1=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=CC=C1N1C(=O)C=CC1=O KNFQJMQMVDKTPU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- QWDCXCRLPNMJIH-UHFFFAOYSA-N 4-formylbenzamide Chemical compound NC(=O)C1=CC=C(C=O)C=C1 QWDCXCRLPNMJIH-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- MEUCHQDLZYLNQY-UHFFFAOYSA-N 5-(aminocarbamothioylamino)-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC(NC(=S)NN)=CC=C1C1=C2C=CC(=O)C=C2OC2=CC(O)=CC=C21 MEUCHQDLZYLNQY-UHFFFAOYSA-N 0.000 description 1
- XHNXJRVXHHTIKS-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=CC=C(C(N)=O)C=N1 XHNXJRVXHHTIKS-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 244000153885 Appio Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000702194 Bacillus virus SPO1 Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 101710172503 Chemokine-binding protein Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- YNHJVXNXMCWXPD-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)NC(NC1=CC=C(C=C1)C(C(=S)OC)C)=O Chemical compound ClC=1C=C(C=CC=1Cl)NC(NC1=CC=C(C=C1)C(C(=S)OC)C)=O YNHJVXNXMCWXPD-UHFFFAOYSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000723382 Corylus Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108030000598 Dinoflagellate luciferases Proteins 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000258963 Diplopoda Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241001427543 Elateridae Species 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101710129170 Extensin Proteins 0.000 description 1
- YTNIXZGTHTVJBW-SCRDCRAPSA-N FMNH2 Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2NC2=C1NC(=O)NC2=O YTNIXZGTHTVJBW-SCRDCRAPSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108091005973 GFP derivatives Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241001343649 Gaussia princeps (T. Scott, 1894) Species 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000255967 Helicoverpa zea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 1
- 101000687448 Homo sapiens REST corepressor 1 Proteins 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000254056 Luciola Species 0.000 description 1
- 241001124207 Luciola mingrelica Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- NPKISZUVEBESJI-AWEZNQCLSA-N N-benzoyl-L-phenylalanine Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 NPKISZUVEBESJI-AWEZNQCLSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NPKISZUVEBESJI-UHFFFAOYSA-N Nalpha-benzoyl-L-phenylalanine Natural products C=1C=CC=CC=1C(=O)NC(C(=O)O)CC1=CC=CC=C1 NPKISZUVEBESJI-UHFFFAOYSA-N 0.000 description 1
- 102100038816 Neuronatin Human genes 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 101710089395 Oleosin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000238590 Ostracoda Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000254058 Photinus Species 0.000 description 1
- 241000133753 Photuris Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 235000003447 Pistacia vera Nutrition 0.000 description 1
- 241001315609 Pittosporum crassifolium Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000191235 Porichthys Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 241001427617 Pyrophorus Species 0.000 description 1
- 102100024864 REST corepressor 1 Human genes 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000003834 Triticum spelta Species 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 244000189228 Triticum turanicum Species 0.000 description 1
- 235000005170 Triticum turanicum Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 101710090398 Viral interleukin-10 homolog Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 125000005337 azoxy group Chemical group [N+]([O-])(=N*)* 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000003157 biological pigment Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000020113 brazil nut Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- KRXYBAYETVZQGL-JRBIQKEYSA-N cyclooctene;(2s)-2,6-diaminohexanoic acid Chemical compound C1CCC\C=C\CC1.NCCCC[C@H](N)C(O)=O KRXYBAYETVZQGL-JRBIQKEYSA-N 0.000 description 1
- CKKWLCWHIOOUMQ-ZSCHJXSPSA-N cyclooctyne;(2s)-2,6-diaminohexanoic acid Chemical compound C1CCCC#CCC1.NCCCC[C@H](N)C(O)=O CKKWLCWHIOOUMQ-ZSCHJXSPSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000004845 diazirines Chemical class 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000001748 luminescence spectrum Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003578 marine toxin Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- RMTLMTYIGIOBQR-UHFFFAOYSA-N n-(2,5-dioxopyrrolidin-1-yl)-4-formylbenzamide Chemical compound C1=CC(C=O)=CC=C1C(=O)NN1C(=O)CCC1=O RMTLMTYIGIOBQR-UHFFFAOYSA-N 0.000 description 1
- WIXAQXKQLNRFDF-UHFFFAOYSA-N n-[4-[7-(diethylamino)-4-methyl-2-oxochromen-3-yl]phenyl]-2-iodoacetamide Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C1=CC=C(NC(=O)CI)C=C1 WIXAQXKQLNRFDF-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 235000020233 pistachio Nutrition 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000768 polyamine Chemical group 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ILLKMACMBHTSHP-UHFFFAOYSA-N tetradecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ILLKMACMBHTSHP-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
Definitions
- the present invention relates to methods for detecting analytes in a sample.
- the methods may also be used to determine the amount of analyte in the sample.
- the present invention also relates to antibody or antibody-like molecules and labelled antigens for use in these methods.
- Methods for detecting an analyte are of critical importance in many industries, including the food, environmental and medical industries. For example, early detection of pathological conditions can permit the identification of these conditions at a stage where successful treatment is more likely. In addition, the detection of trace amounts of a food protein can help prevent severe allergic reactions to contaminated food products.
- ELISA enzyme linked immunosorbent assays
- lateral-flow immunoassays lateral-flow immunoassays
- western-blot immunoassays are widely used
- Biosensors have been developed for detecting an analyte in a sample.
- the ability of biosensors, and biological assays, to respond rapidly and specifically to a wide range of molecules makes them highly relevant to clinical diagnosis/monitoring, environmental and food safety, defence and biosecurity applications.
- Biosensors require biological recognition elements for analyte detection and can include peptides, enzymes, receptors, nucleic acids and antibodies (Bhalla et ah, 2016).
- the identification of biological recognition elements with the required sensitivity and selectivity for detecting a particular analyte at low concentrations remains a fundamental challenge of biosensor development. Accordingly, there is a need for improved methods of detecting and quantifying the amount of an analyte in a sample, preferably methods that can be performed in real time, applied to multiple analytes and/or without having to send samples offsite for analysis.
- the present inventors have identified immunosensors that can be used to detect an analyte in a sample.
- the present inventors have also identified a method of detecting the presence of an analyte in a sample using these immunosensors.
- these immunosensors and methods can be used measure the concentration of an analyte in a sample.
- a method for detecting an analyte in a sample comprising:
- CRET chemiluminescence resonance energy transfer
- a labelled antigen comprising an antigen capable of binding to the antibody or the antibody-like molecule attached to a second component of the CRET pair;
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%;
- step (i) further comprises contacting the sample with a substrate.
- the first component of the CRET pair is a polypeptide and second component of the CRET pair is a polypeptide.
- the first component of the CRET pair comprises a BRET donor domain and second component of the CRET pair comprises a BRET acceptor domain.
- the first component of the CRET pair comprises a BRET acceptor domain and second component of the CRET pair comprises a BRET donor domain.
- the antibody or antibody-like molecule is attached to the first component of the CRET pair via a linker.
- Suitable linkers comprise a polyethylene glycol (PEG) chain, hydrocarbon chain, a polypeptide or a polynucleotide.
- the linker comprises PEGs to PEG 6 o.
- the linker comprises PEG n -L-PEG m , wherein m and n are independently an integer between 0 and 40 and L is a conjugation element.
- the efficiency of energy transfer from the first component to the second component is in the range of 15 to 65% when the labelled antigen is bound to the antibody or antibody-like molecule.
- the attachment between the antibody or antibody-like molecule and the first component of the CRET pair is site-specific. In some embodiments, the first component of the CRET pair is not attached to an antigen binding site of the antibody or antibody-like molecule.
- the first component of the CRET pair is attached to a side-chain of a residue of the antibody or antibody-like molecule.
- the residue is a cysteine.
- the residue is a cysteine involved in inter-chain disulphide bonds.
- the residue is a cysteine in a hinge region of the antibody or antibody-like molecule or the residue is a cysteine involved in a heavy chain-light chain disulphide bond or a combination of both.
- the first component of the CRET pair is attached to the antibody or antibody-like molecule via a carbohydrate moiety.
- the antibody or antibody-like molecule has two attached first components of the CRET pair which are the same.
- the antibody or antibody-like molecule is an IgG, IgA, IgM, IgE, monoclonal antibody, Fab’, rlgG (half antibody), f(ab’)2, nanobody, affibody, anticalin, DARPin, monobody, avimer, microbody, chimeric antibody, scFv, scFv multimer, single domain antibody or single domain fusion antibody.
- the antibody or antibody-like molecule is an IgG, Fab’, rlgG (half antibody) or f(ab’)2.
- the antibody or antibody-like molecule is an IgG.
- the antibody or antibody-like molecule is a monoclonal antibody.
- the antibody or antibody-like molecule is a nanobody.
- the analyte is a small organic molecule, drug, drug metabolite, antibiotic, hormone, allergen, naturally occurring toxin, adulterant, microorganism, peptide, protein, naturally occurring antibody, guar, lipid or nucleic acid.
- the analyte is an allergen.
- the analyte is an antibiotic.
- the analyte is an antibacterial.
- the analyte is an antifungal.
- the analyte is a naturally occurring toxin.
- the analyte is an adulterant.
- the analyte is a microorganism.
- the analyte is a small organic molecule.
- the first or second component of the CRET pair is a bioluminescent protein selected from the group consisting of a luciferase, a b- galactosidase, a lactamase, a horseradish peroxidase, an alkaline phosphatase, a b- glucuronidase or a b-glucosidase.
- the bioluminescent protein is a luciferase selected from the group consisting of Renilla luciferase, a Firefly luciferase, a Coelenterate luciferase, a North American glow worm luciferase, a click beetle luciferase, a railroad worm luciferase, a bacterial luciferase, a Gaussia luciferase, Aequorin, an Arachnocampa luciferase, an Oplophorus gracilirostris luciferase or a biologically active variant or fragment of any one, or chimera of two or more, thereof.
- the bioluminescent protein is Renilla luciferase or a biologically active variant or fragment thereof.
- the bioluminescent protein is RLuc8.
- the first or second component of the CRET pair is capable of modifying a substrate.
- Suitable substrates include, but are not limited to, luciferin, calcium, coelenterazine, furimazine or a derivative, analogue or stabilised derivative of coelenterazine, luciferin or furimazine.
- the first or second component of the CRET pair is a fluorescent acceptor domain.
- the fluorescent acceptor domain is selected from the group consisting of green fluorescent protein (GFP), blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), superfolder GFP, Azami green, mWasabi, TagGFP, Turbo GFP, AcGFP, ZsGreen, T-Sapphire, enhanced CFP (ECFP), CyPET, AmCyanl, Midori-Ishi green, TagCFP, mTFPl (Teal), enhanced YFP (EYFP), GFPS65T, Emerald, Venus, mOrange, Topaz, mCitrine, YPet, TagYFP, PhiYFP, ZsYellow, mBanana, Kusabira Orange, Kusabira Orange2, mOrange, mOrange2, GFPuv, destabilised EGFP (dEGFP), destabilised ECFP (dECFP), destabilized
- the first component of the CRET pair is RFuc8 and the second component of the CRET pair is GFP 2 .
- the separation and relative orientation of the donor domain and the acceptor domain is within ⁇ 50% of the Forster distance of the BRET pair.
- the Forster distance of the BRET pair is between about 4 nm and about 18 nm, or is between about 6 nm and about 12 nm, or is between about 7.5 nm and 10.5 nm.
- step (ii) comprises determining if the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair has been reduced in the presence of the sample. In some embodiments, step (i) comprises
- the method does not require a secondary antibody. In some embodiments, the method further comprises determining the concentration of the analyte in the sample.
- a CRET pair comprising:
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair;
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%.
- an antibody or antibody-like molecule attached to a first component of a CRET pair and capable of binding to
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair
- the efficiency of energy transfer between the first component and the second component is in the range of 10 to 75%.
- a microfluidic system for detecting an analyte in a sample comprising
- At least one reservoir suitable for containing an antibody or antibody-like molecule capable of binding to the analyte attached to a first component of a CRET pair ii) at least one reservoir suitable for containing a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of the CRET pair;
- a microfluidic device comprising one or more microchannels
- iv means for mixing the antibody or antibody-like molecule, the labelled antigen, the sample and a substrate of the first or second component of the CRET pair in the device,
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%;
- the antibody or antibody-like molecule is not fixed to the device. In some embodiments, the antibody or antibody-like molecule, labelled antigen and substrate enter the device through different microchannels. In some embodiments, the microfluidic device comprises at least two input microchannels, wherein one of the input microchannels is for flowing the antibody or antibody-like molecule into the device.
- the microfluidic system can be used to detect the analyte in real time.
- the microfluidic device is designed to enable the detection of two or more analytes.
- the electro-optical sensing device comprises at least two different wavelength channels. In some embodiments, the electro-optical sensing device is capable of simultaneously, or in rapid succession, detecting two different wavelength channels. In some embodiments, the electro-optical sensing device is capable of detecting two different wavelength channels in less than 1 second.
- a method of identifying an antibody or antibody-like molecule capable of binding to an analyte comprising i) obtaining two or more antibodies or antibody-like molecules which have different linkers which link the antibody or antibody-like molecule to a first component of a CRET pair,
- step iv) comprises selecting the antibody or antibody like molecule which, when bound to the labelled antigen, has the higher efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the two or more antibodies or antibody-like molecules.
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the selected antibody or antibody-like molecule, when bound to the labelled antigen is in the range of 50 to 75%.
- the method further comprises:
- each labelled antigen comprising an antigen capable of binding the selected antibody or antibody-like molecule attached to a second component of a CRET pair via an optional linker; wherein the two or more labelled antigens comprise (i) different linkers, and/or (ii) different length antigen, vi) contacting the two or more labelled antigens with the selected antibody or antibody-like molecule capable of binding to an analyte attached to a first component of the CRET pair,
- each labelled antigen comprising an antigen capable of binding an antibody or antibody-like molecule attached to a second component of a CRET pair via an optional linker; wherein the two or more labelled antigens comprise (i) different linkers; and/or (ii) different length antigen, ii) contacting the two or more labelled antigens with an antibody or antibody like molecule capable of binding to an analyte attached to a first component of the CRET pair,
- step iv) comprises selecting the labelled antigen which, when bound to the antibody or antibody-like molecule, has the higher efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the two or more labelled antigens.
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the selected labelled antigen when bound to the antibody or antibody-like molecule is in the range of 50 to 75%.
- the method further comprises:
- each labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair via an optional linker; wherein the two or more labelled antigens comprise (i) different linkers; and/or (ii) different length antigen, iii) contacting the two or more antibodies or antibody-like molecules with the two or more labelled antigens,
- the selected CRET pair comprising one antibody or antibody-like molecule attached to a first component of a CRET pair and a labelled antigen attached to a second component of a CRET pair, wherein, when the selected antibody or antibody-like molecule is bound to the selected labelled antigen, the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%.
- a method of classifying a sample comprising i) contacting a sample with
- an antibody or antibody-like molecule capable of binding to an analyte attached to a first component of a CRET pair
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair, wherein, when the labelled antigen is bound to the antibody or antibody like molecule, the efficiency of energy transfer between the first component and the second component is in the range of 10 to 75%
- step (ii) comprises one or more or all of:
- a method of classifying a sample comprising
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair, c) a substrate of one of the first or second component of the CRET pair, wherein, when the labelled antigen is bound to the antibody or antibody-like molecule, the efficiency of energy transfer between the first component and the second component is in the range of 10 to 75%,
- step (i) comprises
- the method comprises two or more different antibody like molecules each of which binds a different analyte or range of analytes and two or more different labelled antigens
- step v) comprises classifying the sample based on the presence, absence or concentration of each of the analytes or range of analytes.
- the method can be used to classify the sample in real time.
- the antibody or antibody-like molecule is not fixed to the device. In some embodiments, the antibody or antibody-like molecule and substrate enter the device through different microchannels.
- a microfluidic system for classifying a sample comprising
- At least one reservoir suitable for containing an antibody or antibody-like molecule capable of binding to the analyte attached to a first component of a CRET pair ii) at least one reservoir suitable for containing a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of the CRET pair;
- a microfluidic device comprising one or more microchannels
- iv means for mixing the antibody or antibody-like molecule, the labelled antigen, the sample and a substrate of the first or second component of the CRET pair in the device,
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%;
- the microfluidic system comprises two or more different antibody or antibody-like molecules each of which binds a different analyte or range of analytes and two or more different labelled antigens.
- the antibody or antibody-like molecule is not fixed to the device.
- the antibody or antibody-like molecule, labelled antigen and substrate enter the device through different microchannels.
- the microfluidic device comprises at least two input microchannels, wherein one of the input microchannels is for flowing the antibody or antibody-like molecule into the device.
- the microfluidic system can be used to classify samples in real time.
- a method of detecting an analyte in a sample comprising
- an antibody or antibody-like molecule capable of binding to the analyte attached to Renilla lucif erase or a variant thereof; and b) a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to green fluorescent protein 2;
- bioluminescent resonance energy transfer BRET
- CRET based methods described here provide a number of advantages to previously described methods, including increased sensitivity and/or shorter assay times.
- the methods described herein can also be applied to a wide range of analytes.
- composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.
- Figure 1 Illustrative immunosensor for detecting an analyte as defined herein.
- the antibody is attached to a bioluminescent protein and the antigen is attached to a fluorescent protein.
- the Fab’ is attached to a bioluminescent protein and the antigen is attached to a fluorescent protein.
- binding of the analyte (in these embodiments, unlabelled antigen) to the antibody reduces the efficiency of energy transfer between the bioluminescent protein and the fluorescent protein in the presence of a substrate for the bioluminescent protein.
- FIG. 2 Effect of FLAG peptide on BRET ratio of exemplified immunosensors.
- BRET ratio determined for unconjugated RLuc8, and RLuc8 conjugates incubated with FLAG-GFP 2 (61 nM) alone (dark grey bar) or presence of 0.85 mM free FLAG peptide (light grey bar).
- the concentration of RLuc8 in the assay was 5 nM, that of Fab’ - CLICK- RLuc8 was estimated to be 33 nM, Fab’-Solulink-RLuc8 46 nM, antibody - CLICK-RLuc8 66 nM and antibody-Solulink-RLuc8 15 nM.
- FIG. 3 The effect of the order of addition of the FLAG peptide on the response to FLAG peptide addition.
- the FLAG peptide was added to a composition comprising the antibody-CLICK-RLuc8 conjugate before, after or at the same time as FLAG-GFP 2 -and the BRET ratio recorded.
- the concentration of antibody-CLICK-RLuc8 (mAB4/8 RLuc8) was 5 nM, FLAG-GFP 2 150 nM, and FLAG peptide 100 nM.
- Figure 4 - (A) The BRET ratios obtained for Click-PEG-linked 50 nM antibody:RLuc8 conjugates alone (white bar) or in the presence of 100 nM FLAG-GFP 2 (light grey bar), 200 nM FLAG-GFP 2 (dark grey bar) or 200 nM FLAG-GFP 2 and 1 mM FLAG (black bar).
- the PEG linkers used to prepare the conjugates are indicated in their names, such that e.g., mAb-4/8-Luc refers to the conjugate of antibody-PEG4-DBCO and azido-PEG8-RLuc8.
- B BRET ratio of 50 nM Fab’:RLuc8 conjugates alone (light grey bar) or in the presence of 200 nM FLAG-GFP 2 (medium grey bar) or 200 nM FLAG-GFP 2 and 1 pM FLAG peptide (dark grey bar).
- FIG. 7 Schematic of competitive assay for detecting small molecule binding to an immunosensor.
- the nanobody is conjugated to the bioluminescent protein, RLuc8 and the antigen, a TCC analogue, is conjugated to GFP 2 .
- the addition of unconjugated analyte reduces the efficiency of energy transfer between the bioluminescent protein and the fluorescent protein in the presence of a substrate for the bioluminescent protein and a decrease in the BRET 2 ratio is observed.
- SEQ ID NO’ s 1 to 3 - linker sequences.
- the term about refers to +/- 10%, more preferably +/- 5%, even more preferably +/- 1%, of the designated value.
- % concentration is weight/volume (%w/v).
- attachment is defined broadly and is intended to include, without being limited to, covalent and noncovalent interactions.
- a covalent interaction is a chemical linkage between two atoms or radicals formed by the sharing of a pair of electrons (i.e., a single bond), two pairs of electrons (i.e., a double bond) or three pairs of electrons (i.e., a triple bond).
- Covalent interactions are also known in the art as electron pair interactions or electron pair bonds. Examples of covalent attachments include disulphide bonds, amide bonds, thioether bonds and the like.
- Noncovalent interactions are much weaker than covalent interactions, but play a major role in determining the three-dimensional structure of macromolecular structures.
- Noncovalent interactions include, but are not limited to, van der Waals interactions, hydrogen bonds, weak chemical bonds (i.e., via short-range noncovalent forces), hydrophobic interactions, ionic bonds and the like.
- van der Waals interactions hydrogen bonds
- weak chemical bonds i.e., via short-range noncovalent forces
- hydrophobic interactions ionic bonds and the like.
- a review of noncovalent interactions can be found in Alberts et ah, in Molecular Biology of the Cell, 3rd edition, Garland Publishing, 1994.
- Examples of a non-covalent attachment includes the Avidin/streptavidin-biotin complex, antibody/antigen complex, DNA duplex, RNA/DNA duplex, nucleic acid-protein complexes and the like.
- “attached” is preferably covalently attached.
- binding As used herein, the terms “bind,” “binding,” “interact,” “interacting,” “associated with” are intended to include, but are not limited to, non-covalent interactions.
- the term“contacting” refers to bringing two or more chemical molecules to close proximity so that a reaction and/or interaction between the two or more chemical molecules can occur. In some embodiments, the term“contacting” refers to bringing two or more chemical molecules to close proximity so that two or more chemical molecules can form a complex.
- antibody is defined broadly and includes antibodies and antigen binding fragments thereof.
- the term“antibodies” as used herein refers to all isotypes of immunoglobulins, including IgG, IgM, IgA, IgD, and IgE.
- isotype refers to the antibody class (e.g. IgM or IgGl) that is encoded by heavy chain constant region genes.
- immunoglobulin includes the subtypes of these immunoglobulins, such as such as IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, etc. Of these immunoglobulins, IgG are preferred.
- the antibodies may be of any species of origin, including (for example) mouse, rat, rabbit, horse, or human, or may be chimeric antibodies (e.g., M. Walker et al., 1989). Suitable antibodies include a natural antibody from any organism, an engineered antibody or an antibody generated recombinantly for experimental, therapeutic or other purposes.
- antibody as used herein includes antibody fragments which retain the capability of binding to a target antigen, for example, Fab, Fab’, F(ab')2, Fv, scFv fragments, other antigen binding subsequences of antibodies and can include those produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies, and the corresponding fragments obtained from antibodies other than IgG.
- Fab, Fab’ fragment antigen binding subsequences of antibodies
- F(ab')2, Fv, scFv fragments other antigen binding subsequences of antibodies
- These antibody fragments are obtained using conventional procedures, such as proteolytic fragmentation procedures, as described in J. Goding, Monoclonal Antibodies: Principles and Practice, pp 98-118 (N.Y. Academic Press 1983), as well as by other techniques known to those with skill in the art.
- the fragments are screened for utility in the same manner as are intact antibodies.
- Suitable antibodies or antigen binding fragments include, but are not limited to, IgG, IgA, IgM, IgE, monoclonal antibody, Fab’, rlgG (half antibody), f(ab’)2, nanobody, chimeric antibody, scFv, scFv multimer, single domain antibody or single domain fusion antibody.
- the antibody or antibody-like molecule is a monoclonal antibody or an antigen binding fragments thereof.
- telomere binding refers to antibody or antibody-like molecule binding to a predetermined antigen with a preference that enables the antibody to be used to distinguish the antigen from others to an extent that permits the assays described herein.
- the antibody binds with an affinity that is at least two-fold greater than its affinity for binding to antigens other than the predetermined antigen.
- the antibody or antibody-like molecule is forms a complex with the antigen having a dissociation constant (KD) of 100 mM or less, 10 pM or less, 1 pM or less, 500 mM or less, 100 nM or less, 10 nM or less, 1 nM or less, 500 pM or less or 100 pM or less.
- KD dissociation constant
- the dissociation constant is measured at neutral pH and room temperature using a technique known to the person skilled in the art, for example SPR, quartz crustal microbalance or ITC.
- the antibodies or antibody-like molecules useful in the present disclosure can be produced by a variety of techniques known in the art. Monoclonal antibody production may be effected by techniques known in the art.
- the antibodies can be recombinant antibodies.
- the term "recombinant antibody”, as used herein, is intended to include antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic for another species' immunoglobulin genes, antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial antibody library, or antibodies prepared, expressed, created or isolated by any other means that involves splicing of immunoglobulin gene sequences to other DNA sequences.
- the antibodies may be chimeric antibodies produced in accordance with known techniques.
- chimeric monoclonal antibodies may be complementarily determining region-grafted antibodies (or “CDR-grafted antibodies”) produced in accordance with known techniques.
- Monoclonal Fab fragments may be produced in Escherichia coli by recombinant techniques known to those skilled in the art (Huse et ah, 1989).
- an“antibody-like” molecule refers to a molecule, which like an antibody, can specifically bind an antigen but is not structurally related to an antibody.
- an antibody-like molecule is not an antibody or a fragment thereof. Suitable antibody-like molecules include, but are not limited to, affibody, anticalin, DARPin, monobody, avimer, microbody.
- the antibody or antibody-like molecule is an IgG, IgA, IgM, IgE, monoclonal antibody, Fab’, rlgG (half antibody), f(ab’)2, nanobody, affibody, anticalin, DARPin, monobody, avimer, microbody, chimeric antibody, scFv, scFv multimer, single domain antibody or single domain fusion antibody.
- the antibody or antibody-like molecule is an IgG, Fab’, rlgG (half antibody) or f(ab’)2.
- f(ab’)2 is also referred to as Fab’2 and variations thereof.
- the antibody or antibody-like molecule is an IgG or an antigen binding fragment thereof. In some preferred embodiments, the antibody or antibody-like molecule is a monoclonal antibody or an antigen binding fragment thereof. In some embodiments, the antibody or antibody-like molecule is a nanobody.
- a nanobody may also be referred to as a single-domain antibody (sdAb) or a VHH and contains one variable domain of a heavy-chain antibody (VHH), or of a common IgG.
- antibodies in embodiments of the present disclosure provides a number of advantages. Firstly, all antibodies share a common three dimensional structure which is thought to reduce the need to optimise the geometry for each individual immunosensor. Secondly, antibodies have high specificity and affinity for their corresponding antigens and thirdly antibodies can be produced against virtually any antigen.
- antibodies and antibody-like molecules useful herein include engineered antibodies and antibody-like molecules.
- an “engineered antibody or antibody-like molecule” refers to antibody or antibody-like molecule where one or more amino acids of the parent antibody or antibody-like molecule are substituted with a different amino acid. Such substitutions can be made by techniques known to the person skilled in the art, for example site directed mutagenesis.
- the different amino acid may be a naturally occurring amino acid (for example, a cysteine, lysine, glutamic acid, serine or tyrosine) or an unnaturally occurring amino acid. Unnaturally occurring amino acids can allow orthogonal chemical reactivity.
- the unnaturally occurring amino acid carries an orthogonal functional group (such as azide or an alkyne) which can be used to site- specifically attach a first component of the CRET pair by post-translational modification.
- orthogonal functional group such as azide or an alkyne
- unnaturally occurring amino acids include, but are not limited to, 4-acetylphenylalanine, benzoylphenylalanine, acetyllysine, 4-azido-L- phenylalanine, azidohomoalanine, homopropargylglycine, strained cyclooctyne-lysine (SCO-Lys), trans-cyclooct-2-ene-lysine (TCO-Lys), 4-(6-methyl-5-tetrazin-3- yl)aminophenylalanine.
- unnatural amino acid such as those available from Jena Biosecience, Sigma Aldrich, Iris Biotech, Thermo Fisher and Base Click.
- the unnaturally occurring amino acid may be site- specifically incorporated into the antibody or antibody-like molecule by techniques known to the person skilled in the art, for example, amber codon suppression systems (Lang and Chin, 2014; Liu and Schultz, 2010).
- the unnatural amino acid can be useful for site-specific attachment of the first component of the CRET pair at the site of the unnatural amino acid through, for example, a click chemistry.
- the antibody or antibody-like molecule is a cysteine engineered antibody or antibody-like molecule, where one or more amino acids of a parent antibody are replaced with a free cysteine amino acid as disclosed in W02006/034488 .
- a cysteine engineered antibody comprises one or more free cysteine amino acids, preferably having a thiol reactivity value in the range of 0.6 to 1.0.
- a free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge.
- Cysteine engineered antibodies are useful for site-specific attachment of the first component of the CRET pair at the site of the engineered cysteine through, for example, a maleimide or haloacetyl.
- Engineered antibodies or antibody-like molecules preferably retain the antigen binding capability of their wild type, parent antibody counterparts.
- engineered antibodies or antigen-like molecules are capable of binding, preferably specifically, to antigens.
- the term“capable of binding” means that the antibody or antibody-like molecule is forms a complex with the antigen having a dissociation constant (KD) of 100 mM or less, 10 pM or less, 1 pM or less, 500 mM or less, 100 nM or less, 10 nM or less, 1 nM or less, 500 pM or less or 100 pM or less.
- KD dissociation constant
- the antibody or antibody-like molecule useful in the present disclosure is capable of binding to an antigen and an analyte.
- both the“antigen” and “analyte” are capable of binding to the same antibody or antibody-like molecule, preferably at the same binding site. Binding of the antigen and analyte to the antibody or antibody-like molecule is competitive, such that the antigen and analyte bind to the same or overlapping sites on the antibody or antibody-like molecule and only one of the antigen or analyte can bind at a time.
- the antigen and analyte are identical other than the label.
- the antigen is an antibody binding fragment of the analyte.
- the analyte is an antibody binding fragment of the antigen.
- an antibody or antibody-like molecule useful in the present disclosure is an antibody or antibody-like molecule directed an antigen from a pathogen that triggers seroconversion.
- the antibody or antibody-like molecule is a fusion protein comprising an antibody or antibody-like molecule and a first component of a CRET pair.
- the antibody or antibody-like molecule is a fusion protein comprising an nanobody and a first component of a CRET pair (i.e. the nanobody and a first component of a CRET pair form part of the same polypeptide).
- the antibody or antibody-like molecule is not a fusion protein comprising an antibody or antibody-like molecule and a first component of a CRET pair.
- the antibody or antibody-like molecule is covalently attached to the first component of a CRET pair via a linker. Suitable linkers and attachment chemistry are as described herein.
- the antibody or antibody-like molecule is non-covalently attached to the first component of a CRET pair.
- an antibody or antibody-like molecule attached to a first component of a CRET pair and capable of binding to
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair
- the antibody or antibody-like molecule, first component of a CRET pair, an analyte; and labelled antigen are as defined herein.
- a method of identifying an antibody or antibody-like molecule capable of binding to an analyte comprising i) obtaining two or more antibodies or antibody-like molecules which have different linkers which link the antibody or antibody-like molecule to a first component of a CRET pair,
- step iv) selecting at least one antibody or antibody-like molecule which, when bound to the labelled antigen, has an efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair which is in the range of 10 to 75%.
- step iv) comprises selecting the antibody or antibody-like molecule which, when bound to the labelled antigen, has the higher efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the two or more antibodies or antibody-like molecules.
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the selected antibody or antibody-like molecule, when bound to the labelled antigen is in the range of 50 to 75%.
- the term“different linkers” comprises linkers of different length or linkers of different composition (for example, PEG based linkers versus peptide based linkers) or a combination thereof.
- the antibody or antibody-like molecule defined herein is capable of binding to a labelled antigen.
- the term“antigen” refers to a molecule or portion of a molecule that can bind to a recognition site on an antibody or antibody-like molecule.
- the term“labelled antigen” refers to an antigen attached to a second component of a CRET pair. The attachment can be a covalent attachment or a non- covalent attachment.
- the labelled antigen retains the ability to bind to a recognition site on an antibody or antibody-like molecule.
- An antigen can be any compound or molecule of interest for which a diagnostic test is performed, such as a biopolymer or a small molecular bioactive material.
- An antigen can be, for example, a cell, a protein, peptide, carbohydrate, polysaccharide, glycoprotein, hormone, receptor, antibody, vims, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, nucleic acid or lipid, without limitation.
- the antigen is selected from the group consisting of a small organic molecule, drug, drug metabolite, antibiotic, hormone, allergen, peptide, protein, naturally occurring antibody, sugar, lipid or nucleic acid.
- the antigen is selected from the group consisting of a small organic molecule, drug, drug metabolite, antibiotic, hormone, allergen, peptide, protein, sugar, lipid or nucleic acid.
- the antigen is a peptide or protein.
- the antigen is an antibiotic, drug or drug metabolite.
- the antigen is an antibacterial.
- the antigen is an antifungal.
- the antigen is a synthetic antigen similar to or identical to an antigen from a pathogen that triggers seroconversion.
- the antigen is a small organic molecule. As would be understood by the person skilled in the art, an antigen can fall under more than one category.
- the antigen is covalently attached to the second component of the CRET pair.
- the labelled antigen is a fusion protein comprising an antigen and a second component of a CRET pair, that is, both the antigen and the second component of a CRET pair form part of the same polypeptide.
- the labelled antigen is a fusion protein comprising an antigen and a BRET acceptor domain.
- the labelled antigen is a fusion protein comprising an antigen and a fluorescent acceptor domain.
- the labelled antigen is a fusion protein comprising an antigen and GFP, preferably GFP 2 .
- the labelled antigen is a fusion protein comprising an antigen and a BRET donor domain. In some embodiments, the labelled antigen is a fusion protein comprising an antigen and a bioluminescent protein. In one example, the labelled antigen is a fusion protein comprising an antigen and RLuc8. In another example, the labelled antigen is an antigen covalently attached to a second component of a CRET pair via a linker. Any suitable linker may be used. Non limiting examples of linkers and attachment chemistry are as described herein.
- the labelled antigen is a small organic molecule covalently attached to a second component of a CRET pair via a linker. In some embodiments, the labelled antigen is a small organic molecule covalently attached to a second component of a BRET pair via a linker. In some embodiments, the labelled antigen is a small organic molecule attached to a fluorescent acceptor domain via a linker. In some embodiments, the labelled antigen is a small organic molecule covalently attached to a fluorescent protein, via a linker. In some embodiments, the labelled antigen is a small organic molecule covalently attached to GFP, for example GFP 2 , via a linker.
- the labelled antigen is a small organic molecule covalently attached to a BRET donor domain via a linker. In some embodiments, the labelled antigen is a small organic molecule covalently attached to a bioluminescent protein via a linker. In one example, the labelled antigen is a small organic molecule attached to RLuc8 via a linker. In alternative embodiments, the labelled antigen is a peptide or polypeptide covalently attached to a second component of a CRET pair via a linker. In some embodiments, the labelled antigen is a peptide or polypeptide covalently attached to a second component of a BRET pair via a linker.
- the labelled antigen is a peptide or polypeptide attached to a fluorescent acceptor domain via a linker. In some embodiments, the labelled antigen is a peptide or polypeptide covalently attached to a fluorescent protein, via a linker. In some embodiments, the labelled antigen is a peptide or polypeptide covalently attached to GFP, for example GFP 2 , via a linker. In some embodiments, the labelled antigen is a peptide or polypeptide covalently attached to a BRET donor domain via a linker. In some embodiments, the labelled antigen is a peptide or polypeptide covalently attached to a bioluminescent protein via a linker. In one example, the labelled antigen is a peptide or polypeptide covalently attached to RLuc8 via a linker.
- a method of identifying a labelled antigen comprising i) obtaining two or more labelled antigens, each labelled antigen comprising an antigen capable of binding an antibody or antibody-like molecule attached to a second component of a CRET pair via an optional linker; wherein the two or more labelled antigens comprise (i) different linkers; and/or (ii) different length antigen, ii) contacting the two or more labelled antigens with an antibody or antibody like molecule capable of binding to an analyte attached to a first component of the CRET pair,
- step iv) selecting at least one labelled antigen which, when bound the antibody or antibody-like molecule, has an efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair which is in the range of 10 to 75%.
- step iv) comprises selecting the antibody or antibody-like molecule which, when bound to the labelled antigen, has the higher efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the two or more antibodies or antibody-like molecules.
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair of the selected labelled antigen when bound to the antibody or antibody-like molecule is in the range of 50 to 75%.
- the phrase“different length antigen” refers to antigens of different molecular weight, size, number of amino acids.
- the different length antigens may be polypeptides of different length containing the antibody or antibody-like molecule binding epitope.
- the phrase“different linkers” comprises linkers of different length or linkers of different composition (for example, PEG based linkers verses peptide based linkers) or a combination thereof.
- linker refers to a moiety that links one chemical species (for example, an antibody, antibody-like molecule or antigen) to another chemical species (for example, a first component or a second component of a CRET pair).
- a linker can be any biocompatible molecule that contains one or more reactive functional groups or groups that can be functionalised for attachment to one or more chemical species.
- linkers join a reactive functional group or a first component of a CRET pair to an antibody or antibody-link molecule.
- linkers join a reactive functional group or a second component of a CRET pair to an antigen.
- a linker can be any useful structure including, but not limited to, 0-order linkers (i.e., a bond), acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- Further exemplary linkers include substituted or unsubstituted branched or linear C-C substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.
- Other linkers include nucleic acids, peptides and saccharides.
- reactive functional group has the meaning generally recognized in the art of synthetic chemistry, particularly bioconjugate chemistry.
- exemplary reactive functional groups included, without limitation, olefins, acetylenes, alcohols, phenols, ethers, oxides, halides, aldehydes, ketones, carboxylic acids, esters, amides, cyanates, isocyanates, thiocyanates, isothiocyanates, amines, hydrazines, hydrazones, hydrazides, diazo, diazonium, nitro, nitriles, mercaptains, sulfides, disulfides, sulfoxides, sulfones, sulfonic acids, sulfinic acids, acetals, ketals, anhydrides, sulfates, sulfenic acids isonitriles, amidines, imides, imidates, nitrones, hydroxylamines, oximes
- linker which achieves the above function may be utilized.
- suitable linkers include those comprising hydrocarbon chains (e.g. unbranched alkylene moieties), peptide chains, PEG-type or other polyether-type groups, and other polymeric groups (such as polyhydroxyacids).
- the linker consists of a chain of atoms linking the two chemical species, the chain consisting of from 50 to 500, from 100 to 500, from 150 to 500, from 200 to 500, from 250 to 500, from 300 to 500, from 350 to 500, from 400 to 500 atoms.
- the linker consists of a chain of atoms linking the two chemical species, the chain consisting of from 2 to 500, 2 to 450, 2 to 400, 2 to 350, 2 to 300, 2 to 250, 2 to 200, 2 to 150, 2 to 100, 2 to 50, from 2 to 40, from 2 to 30, from 2 to 20, from 2 to 10 atoms.
- linkers include, but are not limited to, polypeptides, polynucleotides, polyalkylene glycol, polyalkylene glycol where at least one oxygen of the polyalkylene glycol chain is substituted with nitrogen, polyamine (Herve et ah, 2008), peptide nucleic acid (PNA) (Egholm et ah, 2005), locked nucleic acid (LNA) (Singh et ah, 1998), triazoles, piperazines, oximes, thiazolidines, aromatic ring systems, alkanes, alkenes, alkynes, cyclic alkanes, cyclic alkenes, amides, thioamides, ethers, and hydrazones.
- PNA peptide nucleic acid
- LNA locked nucleic acid
- the linking element comprises or is selected from the group consisting of alkyl chain, glycol, polyglycol, ether, polyether, polyamide, polyester, amino acid, peptide, polypeptide or polynucleotide. In some embodiments, the linking element is a peptide or polypeptide. In some embodiments, the linking element is polyethylene glycol or polypropylene glycol.
- the linker comprises hydrocarbons (e.g. the central spacer group may be an alkylene group), branched or unbranched, and said hydrocarbons being of chain length in the range of from C2 - C250, C20- C250, C40 - C250, C60 -C250, Cso - C250, Cioo - C250, C120 - C250, Ci40 - C250, Ci60 - C250, Ci80 - C250, C200 - C250, C220 - C250, or, at least C2, at least C20, at least C40, at least C50, at least C60, at least C70, at least Cso, at least C90, at least Cioo.
- hydrocarbons e.g. the central spacer group may be an alkylene group
- the hydrocarbons being of chain length in the range of from C2 - C250, C20- C250, C40 - C250, C60 -C250, Cso - C250, Ci
- the linker comprises a branched or unbranched Ci so- C250, C200- C240, or C210 - C230 hydrocarbon group. In an example, the linker comprises a branched or unbranched C150 - C250, or Ciso - C220 hydrocarbon group. In some examples, the linker comprises a branched or unbranched Ciso - C220 hydrocarbon group. In some examples, the linker comprises a Ci, C2, C3, C 4 , C 5 , Ce, C 7 , Cg, C9, C10, C12, Ci4, Ci6, Ci8, or C20 alkylene group, i.e. the linker comprsises (03 ⁇ 4) where n is an integer between 1 and 20.
- the linker comprises a C2 alkylene group (i.e. -CH2-CH2-).
- the linker can comprise polyalkylene glycol.
- Suitable polyalkylene glycols include polyethylene glycol (PEG), polypropylene glycol or methoxypolyethylene glycol (mPEG) and derivatives thereof, such as for example 0,0'-bis(2-aminopropyl)-polyethylene glycol 500 and 2,2'-(ethylene dioxide)diethyl amine.
- PEG is a polymer of ethylene glycol and, depending on substitutions, can have the chemical formula C 2n+2 H 4n+6 0 n+2 .
- a PEG group is a group base on the subunit -(CH2CH2O)-, i.e. the term PEGn refers to a group of formula - (CthCthO .
- the linker may comprise PEGn, wherein n is the number of PEG units.
- the linker comprises PEG having up to about 72 ethylene glycol moieties, up to about 60 ethylene glycol moieties, up to about 48 ethylene glycol moieties, up to about 36 ethylene glycol moieties, up to about 32 ethylene glycol moieties, up to about 28 ethylene glycol moieties, up to about 20 ethylene glycol moieties, up to about 12 ethylene glycol moieties, or up to about 8 ethylene glycol moieties.
- the linker comprises PEG having 8 or more ethylene glycol moieties, 12 or more ethylene glycol moieties, 20 or more ethylene glycol moieties, 28 or more ethylene glycol moieties, 32 or more ethylene glycol moieties, 36 or more ethylene glycol moieties, 40 or more ethylene glycol moieties, 48 or more ethylene glycol moieties, 60 or more ethylene glycol moieties, or 70 or more ethylene glycol moieties.
- the linker may comprise PEGn having a chain length of PEG2 - PEG100, PEG10 - PEG90, PEG20 - PEG80, PEG30 - PEG70, PEG40 - PEG60, PEG45 - PEG55, or, at least PEG2, at least PEG5, at least PEG10, at least PEG15, at least PEG20, at least PEG25, at least PEG30, at least PEG35, at least PEG40, at least PEG45, at least PEG50.
- Other useful polyalkylene glycols are polypropylene glycols, polybutylene glycols, PEG-glycidyl ethers, and PEG- oxyc arbonylimidazole .
- the linker comprises PEG n -L-PEG m , wherein m and n are independently an integer between 0 and 100 and L is a conjugation element. In some embodiments, n and m are independently selected from 4, 8, 12, 16, 20, 24, 28, 32, 36 or 40.
- the term“conjugation element” refers to any chemical species formed by the reaction of two reactive functional groups.
- the conjugation element is formed by the reaction of DBCO with an azide
- the conjugation element is formed from the reaction of an azide containing molecule and a DBCO containing molecule.
- the linker is a polyurethane, polyhydroxy acid, polycarbonate, polyimide, polyamide, polyester, polysulfone comprising 1-100, 1 - 90, 1 - 80, 1 - 70, 1 - 60, 10 - 60, 20 - 60, 30 - 60, 40 - 60, or, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, at least 48, at least 52, at least 56, at least 60, or less than 60, less than 56, less than 52, less than 48, less than 44, less than 40, less than 36, less than 32, less than 28, less than 24, less than 20, less than 16, less than 12, less than 8, less than 4 monomer units.
- the linker comprises an oligonucleotide.
- the oligonucleotide can comprise both nucleoside bases or modified nucleoside bases or both.
- the linking element can have up to about 100 nucleoside bases and/or modified nucleoside bases. In one embodiment, the linking element can have up to about 100, up to about 90, up to about 80, up to about 70, up to about 60, up to about 50, up to about 40, up to about 30, up to about 20, up to about 10, up to about 5, or up to about 2 nucleoside bases and/or modified nucleoside bases.
- the nucleic acid linker can have a length of 1 - 100, 20 - 80, 40 - 60, 45 - 55, or, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least.35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100 nucleoside bases and/or modified nucleoside bases.
- the linker comprises an amino acid or a chain of amino acids or peptides.
- the linker may comprise a sequence of in the range of from 1 - 100, 20 - 80, 40 - 60, 45 - 55, or, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least
- the linker can comprise dipeptides, tripeptides, tetrapeptides, pentapeptides and so on.
- the amino acids can be naturally or unnaturally occurring amino acids or a combination thereof.
- the peptide or polypeptide can comprise modified amino acids.
- the linker can comprise amino acids selected from L-amino acids, D-amino acids or b-amino acids.
- the linker can comprise b- peptides.
- the constituents of the amino acid linker are L amino acids.
- the linker can comprise a Cys, a Thr, a Glu, a Gly, a Ser or a Lys amino acid residue.
- the linker comprises a Gly and a Ser.
- the linker can comprise GlySerSer or GlySerSer repeats (GlySerSer) n ,
- the linker can comprise (GlySerSer) n -X-(GlySerSer) m , where n and m are independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
- X is a conjugation element, a Cys, a Thr, a Glu or a Lys.
- the linker can comprise (GlySerSer) n -XY-(GlySerSer) m , where n and m are independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and X is a conjugation element, a Cys, a Thr, a Glu or a Lys and Y is any amino acid.
- the linker can comprise (GlySerSer) n -X(Y)a-(GlySerSer) m , where n and m are independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and X is a conjugation element, a Cys, a Thr, a Glu or a Lys, Y is any amino acid or combination of amino acids and a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
- the linker can comprise GlySer or GlySer repeats ((GlySer) n ).
- the linker can comprise (GlySer) n where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
- the linker can comprise (GlySer) n -X a - (GlySer) m , where n and m are independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
- X is a conjugation element, a Cys, a Thr, a Glu or a Lys
- Y is any amino acid or combination of amino acids and a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
- the linker comprises a high affinity Gin substrate for microbial transglutaminase (Oteng-Pabi et ah, 2014).
- the linking element comprises a peptide having the sequence selected from the group consisting of
- the linking element comprises a sortase recognition sequence (Theile et ah, 2013).
- the linking element comprises a peptide having the sequence LPXT, where X is any amino acid (SEQ ID NO: 3).
- sortase mediated reactions can be used to label the N-terminus of the first or second component of the CRET pair.
- the linker further comprises a spacer sequence.
- the spacer sequence comprises one or more glycine, serine and/or threonine residues, for example, as defined above.
- the linker can comprise molecules selected from the group consisting of thioxo-amino acids, hydroxy acids, mercapto acids, dicarbonic acids, diamines, dithioxocarbonic acids, acids and amines.
- the linker or tether comprises derivatised amino acid sequences or peptide nucleic acids (PNAs).
- the linker is a combination of the above referenced components.
- the antibody or antibody-like molecule is attached to the first component of the CRET pair via a peptide linker such that the antibody or antibody- like molecule and the first component of the CRET pair form a single polypeptide.
- the antigen is attached to the second component of the CRET pair via a peptide linker such that the antigen and the second component of the CRET pair form a single polypeptide.
- linkers Numerous methods for preparing the above referenced "linkers” and attaching them to a polypeptide, such as an antibody, antibody-like molecule, antigen, first or second component of a CRET pair, are known in the art and are suitable for use in the present disclosure.
- the antibody or antibody-like molecule is attached to the linker via a reactive functional group and the first component of the CRET pair is attached to the linker via a reactive functional group.
- the antigen is attached to the linker via a reactive functional group and the second component of the CRET pair is attached to the linker via a reactive functional group.
- the linker comprises one or more reactive functional groups.
- the reactive functional group can react with a chemical group in the antibody, antibody-like molecule, antigen, first component of the CRET pair or second component of the CRET pair by any means of chemical reaction to form the molecules described herein.
- the site of attachment to the antibody, antibody-like molecule, antigen, first component of the CRET pair or second component of the CRET pair includes primary amines (-Nth), carboxyls (-COOH or CO), sulfhydryls (-SH), carbonyls (CHO) and carbohydrates. Any suitable reactive functional group may be used.
- the reactive functional group is selected from the group consisting of a sulfhydryl reactive moiety, an amine reactive moiety and a carbonyl reactive moiety.
- the reactive functional group is a group which reacts with a sulfhydryl reactive moiety, an amine reactive moiety and/or a carbonyl reactive moiety.
- the reactive moiety may include of a free cysteine residue, free lysine residue or a carbonyl group.
- the linker is provided with a sulfhydryl reactive moiety which is reactive with a free cysteine (e.g., a naturally occurring cysteine or a cysteine introduced by mutation) the antibody, antibody-like molecule, antigen, first component of the BRET pair or second component of the BRET pair to form a covalent linkage therebetween.
- the linking element is provided with an amine reactive moiety which is reactive with a lysine residue (e.g., a naturally occurring lysine or a lysine introduced by mutation) in the antibody, antibody like molecule, antigen, first component of the BRET pair or second component of the BRET pair to form a covalent linkage therebetween.
- the linking element is provided with a carbonyl reactive moiety which is reactive with a carbonyl group in the antibody, antibody-like molecule, antigen, first component of the BRET pair or second component of the BRET pair to form a covalent linkage therebetween.
- the linking element is provided with a free cysteine or a free lysine which is reactive with a sulfhydryl reactive moiety in the antibody, antibody-like molecule, antigen, first component of the BRET pair or second component of the BRET pair to form a covalent linkage therebetween.
- the linking element is provided with a free lysine which is reactive with an amine reactive moiety in the antibody, antibody-like molecule, antigen, first component of the BRET pair or second component of the BRET pair to form a covalent linkage therebetween.
- the linking element is provided with a carbonyl group which is reactive with a carbonyl reactive moiety in the antibody, antibody-like molecule, antigen, first component of the BRET pair or second component of the BRET pair to form a covalent linkage therebetween.
- Sulfhydryl reactive moieties include thiol, triflate, tresylate, aziridine, oxirane, S-pyridyl, haloacetyl (bromo- or iodo-), maleimidobenzoyl sulfosuccinimide ester, vinyl sulfone, pyridyldisulfide, thiosulfonate isocyanate and epoxide groups or maleimide moieties.
- Preferred sulfhydryl reactive moieties include maleimide, acrylamide, phenylcarbonylacrylamide and iodo acetamide.
- Amine reactive moieties include active esters (including, but not limited to, succinimidyl esters, sulfosuccinimidyl esters, tetrafluorophenyl esters, and sulfodichlorophenol esters), isothiocyanates, dichlorotriazines, aryl halides, acyl azides and sulfonyl chlorides. Of these amine reactive moieties, active esters are preferred reagents as they produce stable carboxamide bonds (see, for example, Banks and Paquette, 1995). Carbonyl reactive moieties include primary amines such as hydrazides and alkoxyamines.
- Carbonyl containing moieties include aldehydes (RCHO) and ketones (RCOR').
- the aldehyde is created by periodate-oxidation of a sugar group in the linking element.
- suitable reactive functional groups capable of reacting with an aldehyde group include amines, hydrazides and alkoxyamines.
- reactive functional groups include diazirines, aryl azides and isocyanates.
- the linker when the linker comprises PEG it may also comprise one or more reactive functional groups selected from the group consisting of maleimide (Mai), N-hydroxysuccinimide, dibenzocyclooctyne (DBCO) and azide which can be used to attach the PEG linker to the antibody, antibody-like molecule, antigen, first component of the CRET pair, second component of the CRET pair or additional linker.
- Reactive functional groups selected from the group consisting of maleimide (Mai), N-hydroxysuccinimide, dibenzocyclooctyne (DBCO) and azide which can be used to attach the PEG linker to the antibody, antibody-like molecule, antigen, first component of the CRET pair, second component of the CRET pair or additional linker.
- the linker comprises azido-(PEG)n-NHS ester, DBCO-(PEG)n-Mal, mal- (PEG)n-NHS or Mal-(PEG)n-Mal, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40.
- the linker when the linker comprises a peptide it may also comprise a cysteine residue and/or a lysine residue.
- the linker is functionalised and attached to a first or second component of a CRET pair using a carbodiimide compound (e.g. EDC).
- the linker is functionalised and attached to a first or second component of a CRET pair using a carbodiimide compound (e.g. EDC) in the presence of an N- hydroxysuccinimide compound (e.g. sulfo-NHS).
- the linker can be functionalised and attached using various "click chemistry" strategies such as those disclosed in Kolb et al. (2001), WO 2003/101972 and Malkoch et al. (2005).
- the linker can be functionalised and attached using Solulink bioconjugation chemistry (also referred to as Hydralink) (Dirksen et al., 2006).
- Solulink bioconjugation chemistry is based on the reaction of an aromatic hydrazine with an aromatic aldehyde, to form a stable bis-arylhydrazone conjugate ion element as shown below:
- the linker comprises an aldehyde- aromatic hydrazine linker formed from the reaction of 4-formylbenzamide and 6-hydrazinonicotinamide.
- linkers can be attached via a transglutaminase reaction as discussed above. In a further example, “linkers” can be attached via a sortase reaction as discussed above.
- the antibody or antibody-like molecule is covalently attached to the first component of the CRET pair via a linker.
- the linker (or part thereof) is an integral part of the antibody or antibody-like molecule (for example, a naturally occurring cysteine in the antibody or antibody-like molecule such that the antibody or antibody-like molecule and first component of the CRET pair are directly bound via the side-chain of the naturally occurring cysteine).
- the linker (or part thereof) is an integral part of the first component of the CRET pair (for example, the side-chain of the naturally occurring cysteine, histidine, serine, tyrosine or lysine or enzyme recognition sequences, preferable a lysine or cysteine).
- the linker is a separate chemical entity which attaches the antibody or antibody-like molecule to the first component of the CRET pair.
- the molecules described herein may comprise one or more linkers.
- linkers For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 linkers.
- an antibody or antibody-like molecule may have a first, a second, a third, a fourth or fifth linker for attaching the first component of the CRET pair donor or acceptor domain.
- the molecules described herein comprise one linker.
- the number of linkers is dependent on the number of cysteine residues present in the hinge region of the antibody or fragment hereof.
- the length of the linker attaching the first component of the CRET pair to the antibody or antibody-like molecule allows the first component of the CRET pair attached to the antibody or antibody-like molecule to be a suitable distance from the second component of the CRET pair when the antigen is bound to the antibody.
- the length of the linker can impact CRET (for example, BRET) between the first and second component of the CRET pair.
- the preferred length of the linker can vary depending on the selection of the first and second component of the CRET pair.
- the preferred length of the linker can be determined using methods defined herein and techniques known to the person skilled in the art.
- the antigen is covalently attached to the second component of the CRET pair via a linker.
- the linker or part thereof is an integral part of the antigen (for example, a naturally occurring cysteine, lysine or sugar moiety).
- the linker or part thereof is an integral part of the second component of the CRET pair (for example, the side-chain of the naturally occurring cysteine or lysine).
- the linker is a separate chemical moiety which attaches the antigen to the second component of the CRET pair.
- the antibody, antibody-like molecule, antigen, first component of the CRET pair or second component of the CRET pair are functionalised for attachment to the linker.
- these molecules can be reacted with a chemical moiety which facilitates attachment of the antibody, antibody-like molecule, antigen, first component of the CRET pair or second component of the CRET pair to the linker.
- the site of attachment for the antibody or antibody-like molecule to the first component of the CRET pair and the antigen to the second component of the CRET pair should not significantly interfere with the binding of the antigen to the antibody or antibody-like molecule.
- the attachment of the first and/or second component of the CRET pair reduces binding of the antigen to the antibody or antibody-like molecule by less than 50%, less than 60%, less than 70%, less than 75%, less than 80%, less than 85%, less than 90% less than 95%, less than 98% or less than 99% when compared to binding of the antigen to the antibody or antibody-like molecule when not attached to the first and/or second component of the CRET pair.
- the labelled antigen is capable of binding to the antibody or antibody-like molecule attached to the first component of the CRET pair.
- a complex consisting of the antibody or antibody-like molecule attached to the first component of the CRET pair forms and the labelled antigen has a dissociation constant (KD) of 100 mM or less, 10 mM or less, 1 pM or less, 500 mM or less, 100 nM or less, 10 nM or less, 1 nM or less, 500 pM or less or 100 pM or less.
- KD dissociation constant
- the attachment should also not significantly interfere with the activity of the first and/or second components of the CRET pair.
- the attachment reduces the activity of the first and/or second component of the CRET pair by less than 50%, less than 60%, less than 70%, less than 75%, less than 80%, less than 85%, less than 90% less than 95%, less than 98% or less than 99% when compared to the activity of the first and/or second component of the CRET pair when not attached to the antigen, antibody or antibody-like molecule.
- the first component of the CRET pair is not attached to an antigen binding site of the antibody or antibody-like molecule. In some embodiments, the attachment between the antibody or antibody-like molecule and the first component of the CRET pair is site-specific. In some embodiments, the first component of the CRET pair is attached to a side-chain of a residue of the antibody or antibody-like molecule.
- the residue can be a cysteine, lysine, glutamic acid or aspartic acid. Preferably, the residue is a cysteine. In some embodiments, the cysteine is a naturally occurring cysteine, for example one present in the native sequence.
- the cysteine is an engineered cysteine that is not present in the sequence of the native antibody or antibody-like molecule.
- the cysteine is one that was involved in inter-chain disulphide bonds. Prior to attachment, the inter-chain disulphide bond is reduced by treatment with a reducing agent, for example, TCEP (tris(2-carboxyethyl)phosphine), DTT (dithiothreitol), MEA (2-mercaptoethlyamine, cysteamine) or 2-mercaptoethanol.
- a reducing agent for example, TCEP (tris(2-carboxyethyl)phosphine), DTT (dithiothreitol), MEA (2-mercaptoethlyamine, cysteamine) or 2-mercaptoethanol.
- the reducing agent is a mild reducing agent, such as MEA or TCEP (see, for example, Kirley et al., 2016).
- the reaction conditions can be varied (for example, concentration of reducing agent, pH, temperature, reducing agent, time) to optimise the yield of the partially reduced antibody.
- the partially reduced antibody or antibody like molecule is subjected to mild oxidation, for example to promote reformation of disulphide bonds between cysteine residues located in close proximity.
- the partially reduced antibody is treated with dehydroascorbic acid (DHAA).
- DHAA dehydroascorbic acid
- the residue is a cysteine in a hinge region of the antibody or antibody-like molecule or the residue is a cysteine involved in a heavy chain-light chain disulphide bond or a combination of both.
- the antibody or antibody-like molecule is an antibody having a hinge region and the point of attachment is a cysteine in the hinge region of the antibody.
- the first component of the CRET pair is attached to N- or C-terminus of the antibody or antibody-like molecule.
- the attachment is via a peptide bond.
- Antibodies or antibody-like molecules can be post translationally modified (for example, glycosylation).
- the first component of the CRET pair is attached to the antibody or antibody-like molecule via the post-translational modification.
- the first component of the CRET pair can be attached to the antibody or antibody-like molecule via a carbohydrate moiety refers to .
- carbohydrate moiety includes saccharide, polysaccharide, oligosaccharide, and sugar the definitions of which are well known in the art of carbohydrate chemistry. Methods of attaching a polypeptide to a carbohydrate moiety of an antibody or antibody-like molecule are known to the person skilled in the art. Methods for attaching a polypeptide to a carbohydrate moiety of an antibody are described, for example, in US 6,218,160.
- the second component of the CRET pair is site- specifically attached to the antigen. In some embodiments, the second component of the CRET pair is attached to a side-chain of a residue of the antigen.
- the residue can be a cysteine, lysine, glutamic acid or aspartic acid. Preferably, the residue is a cysteine or a lysine.
- the residue is a naturally occurring residue, for example one present in the native sequence of the polypeptide. In alternative embodiments, the residue is an engineered residue that is not present in the native sequence of the polypeptide.
- the second component of the CRET pair is attached to N- or C-terminus of the antigen. In an example, the attachment is via a peptide bond. For example, the second component of the CRET pair and the antigen for a single polypeptide.
- the antigen is attached to a side-chain of a residue of the second component of the CRET pair.
- the residue can be a cysteine, lysine, glutamic acid or aspartic acid.
- the residue is a cysteine or a lysine.
- the residue is a lysine.
- the residue is a naturally occurring residue, for example one present in the native sequence of the polypeptide.
- the residue is an engineered residue that is not present in the native sequence of the polypeptide.
- Binding of an analyte to the antibody or antibody-like molecule of the present disclosure results in a reduction in the efficiency of energy transfer between the first and second components of the CRET pair.
- the reduction in the efficiency of energy transfer indicates that the analyte is present in the sample (see Figure 1).
- Chemiluminescence is the result of chemical reactions between an organic dye and an oxidizing agent in the presence of a catalyst. Chemiluminescence emission occurs as the energy from the excited states of organic dyes, which are chemically induced, decays to ground state. The duration and the intensity of the chemiluminescence emission are mostly dependent on the extent of the chemical reagents present in the reaction solution.
- the term "chemiluminescence” is used herein to encompass bioluminescence, which relies upon the activity of an enzyme.
- chemiluminescent resonance energy transfer CRET
- CRET chemiluminescent resonance energy transfer
- BRET bioluminescent resonance energy transfer
- One of the first component or the second component of the CRET pair comprise a donor domain.
- the first component of the CRET is a donor domain.
- the second component of the CRET is a donor domain.
- the term“donor domain” means a molecule that emits light, for example a molecule which, when irradiated with light of a certain wavelength, emits light or a molecule which causes the emission of light as the result of a chemical reaction.
- the donor domain is capable of serving as a donor domain in a chemiluminescent resonance energy transfer pair (for example, in a BRET pair) and, depending on context, is also referred to herein as a“chemiluminescent resonance energy transfer donor domain” or“CRET donor domain”.
- the CRET pair is a BRET pair and the donor domain is referred to as a“bioluminescent resonance energy transfer donor domain” or“BRET donor domain”.
- Suitable donor domains include chemiluminescent domains which are capable of serving as a donor domain in a BRET pair.
- the donor domain can be a chemiluminescent donor domain.
- the chemiluminescent donor domain is a bioluminescent protein.
- bioluminescent protein refers to any protein capable of acting on a suitable substrate to generate luminescence. It is understood in the art that a bioluminescent protein is an enzyme which converts a substrate into an activated product which then releases energy as it relaxes. The activated product (generated by the activity of the bioluminescent protein on the substrate) is the source of the biolumine scent protein-generated luminescence that is transferred to the acceptor molecule.
- bioluminescent protein can be used in the sensors of the present disclosure.
- bioluminescent proteins that can be employed in this invention (see, for example, Table 1).
- Light-emitting systems have been known and isolated from many luminescent organisms including bacteria, protozoa, coelenterates, molluscs, fish, millipedes, flies, fungi, worms, crustaceans, and beetles, particularly click beetles of genus Pyrophorus and the fireflies of the genera Photinus, Photuris, and Luciola. Additional organisms displaying bioluminescence are listed in WO 00/024878, WO 99/049019 and Viviani (2002).
- lucif erases which catalyse an energy-yielding chemical reaction in which a specific biochemical substance, a luciferin (a naturally occurring fluorophore), is oxidized by an enzyme having a luciferase activity
- a luciferin a naturally occurring fluorophore
- a luciferase activity Hastings, 1996.
- prokaryotic and eukaryotic including species of bacteria, algae, fungi, insects, fish and other marine forms can emit light energy in this manner and each has specific luciferase activities and luciferins which are chemically distinct from those of other organisms.
- Luciferin/luciferase systems are very diverse in form, chemistry and function.
- Bioluminescent proteins with luciferase activity are thus available from a variety of sources or by a variety of means. Examples of bioluminescent proteins with luciferase activity may be found in US 5,229,285, 5,219,737, 5,843,746, 5,196,524, and 5,670,356. Two of the most widely used luciferases are: (i) Renilla luciferase (from R.
- reniformis a 35 kDa protein, which uses coelenterazine as a substrate and emits light at 480 nm (Lorenz et ah, 1991); and (ii) Firefly luciferase (from Photinus pyralis ), a 61 kDa protein, which uses luciferin as a substrate and emits light at 560 nm (de Wet et al thread 1987).
- Gaussia luciferase (from Gaussia princeps) has been used in biochemical assays (Verhaegen et ah, 2002). Gaussia luciferase is a 20 kDa protein that oxidises coelenterazine in a rapid reaction resulting in a bright light emission at 470 nm.
- Luciferases useful for the present invention have also been characterized from Anachnocampa sp (WO 2007/019634). These enzymes are about 59 kDa in size and are ATP-dependent luciferases that catalyse luminescence reactions with emission spectra within the blue portion of the spectrum.
- Biologically active variants or fragments of naturally occurring bioluminescent protein can readily be produced by those skilled in the art.
- Three examples of such variants useful for the invention are RLuc2 (Loening et ah, 2006), RLuc8 (Loening et al., 2006) and RLuc8.6-535 (Loening et al., 2007) which are each variants of Renilla luciferase.
- the sequence of the donor domain is chosen to have greater thermal stability than molecules incorporating native Renilla luciferase.
- RLuc2 or RLuc8 are convenient examples of suitable choices, which consequently exhibit >5x or >10x higher luminance than sensors incorporating the native Renilla luciferase sequence. Such enhanced luminance has significant benefits as it permits more economical use of reagents for any given time resolution.
- non-luciferase, bioluminescent proteins that can be employed in this invention are any enzymes which can act on suitable substrates to generate a luminescent signal.
- enzymes include b-galactosidase, lactamase, horseradish peroxidase, alkaline phosphatase, b-glucuronidase and b-glucosidase.
- Synthetic luminescent substrates for these enzymes are well known in the art and are commercially available from companies, such as Tropix Inc. (Bedford, MA, USA).
- the bioluminescent protein is a luciferase, a b- galactosidase, a lactamase, a horseradish peroxidase, an alkaline phosphatase, a b- glucuronidase or a b-glucosidase.
- the bioluminescent protein is luciferase.
- Suitable luciferase include, but are not limited to a Renilla luciferase, a Firefly luciferase (e.g.
- PpyRE8, PpyRElO a Coelenterate luciferase, a North American glow worm luciferase, a click beetle luciferase, a railroad worm luciferase, a bacterial luciferase, a Gaussia luciferase, Aequorin, an Arachnocampa luciferase, an Oplophorus gracilirostris luciferase or a biologically active variant or fragment of any one, or chimera of two or more, thereof.
- the preferred luciferase is RLuc8 or a variant thereof.
- a "biologically active fragment” is a portion of a polypeptide as described herein which maintains a defined activity of the full-length polypeptide.
- a "biologically active variant” is a molecule which differs from a naturally occurring and/or defined molecule by one or more amino acids but maintains a defined activity, such as defined above for biologically active fragments.
- Biologically active variants are typically least 50%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, more preferably at least 97%, and even more preferably at least 99% identical to the naturally occurring and/or defined molecule.
- a bioluminescent protein with a small molecular weight is used to prevent an inhibition of the interaction due to steric hindrance.
- the bioluminescent protein preferably consists of a single polypeptide chain. Also the bioluminescent proteins preferably do not form oligomers or aggregates.
- the bioluminescent proteins Renilla luciferase, Gaussia luciferase and Firefly luciferase meet all or most of these criteria.
- the chemiluminescent donor domain is capable of modifying a substrate.
- substrate refers to any molecule that can be used in conjunction with a chemiluminescent donor to generate or absorb luminescence. The choice of the substrate can impact on the wavelength and the intensity of the light generated by the chemiluminescent donor.
- the bioluminescent protein has a substrate selected from luciferin, calcium, coelenterazine, furimazine or a derivative, analogue or stabilised derivative of coelenterazine, luciferin or furimazine.
- Coelenterazine is a widely known substrate which occurs in cnidarians, copepods, chaetognaths, ctenophores, decapod shrimps, mysid shrimps, radiolarians and some fish taxa (Greer and Szalay, 2002).
- coelenterazine analogues/derivatives are available that result in light emission between 418 and 547 nm (Inouye et al., 1997, Loening et al., 2007).
- a coelenterazine analogue/derivative 400A, DeepBlueC
- has been described emitting light at 400 nm with Renilla luciferase (WO 01/46691).
- coelenterazine analogues/derivatives are EnduRen, Prolume purple, Prolume purple II, Prolume purple III, ViviRen and Furimazine.
- coelenterazine analogues/derivatives include, but are not limited to, compounds disclosed in PCT/US2013057660 and US20140302539.
- luciferin is defined broadly and refers to a class of light-emitting biological pigments found in organisms capable of bioluminescence as well as synthetic analogues or functionally equivalent chemicals, which are oxidised in the presence of the enzyme luciferase to produce oxyluciferin and energy in the form of light.
- D-luciferin, or 2-(6-hydroxybenzothiazol-2-yl)-2-thiazoline-4-carboxylic acid was first isolated from the firefly Photinus pyralis.
- luciferin also includes derivatives or analogues of luciferin.
- luciferin In addition to entirely synthetic luciferin, such as cyclic alkylaminoluciferin (CycLucl), there are at least five general types of biologically evolved luciferin, which are each chemically different and catalysed by chemically and structurally different luciferases that employ a wide range of different cofactors.
- First is firefly luciferin, the substrate of firefly luciferase, which requires ATP for catalysis (EC 1.13.12.7).
- Bacterial luciferase is FMNH-dependent.
- dinoflagellate luciferin a tetrapyrrolic chlorophyll derivative found in dinoflagellates (marine plankton), the organisms responsible for night-time ocean phosphorescence.
- Dinoflagellate luciferase catalyses the oxidation of dinoflagellate luciferin and consists of three identical and catalytically active domains.
- imidazolopyrazine vargulin which is found in certain ostracods and deep-sea fish, for example, Porichthys.
- Last is coelenterazine (an imidazolpyrazine), the light-emitter of the protein Aequorin, found in radiolarians, ctenophores, cnidarians, squid, copepods, chaetognaths, fish and shrimp.
- the bioluminescent protein requires a co-factor.
- co-factors include, but are not necessarily limited to, ATP, magnesium, oxygen, FMNFb, calcium, or a combination of any two or more thereof.
- One of the first component or the second component of the CRET pair comprise an acceptor domain.
- the first component of the CRET is an acceptor domain.
- the second component of the CRET is an acceptor domain.
- the acceptor domain is capable of serving as an acceptor domain in a chemiluminescense resonance energy transfer pair (for example, in a BRET pair) and, depending on context, is also referred to herein as a“chemiluminescent resonance energy transfer acceptor domain” or “CRET acceptor domain”.
- the CRET pair is a BRET pair and the acceptor domain is referred to as a “bioluminescent resonance energy transfer donor domain” or“BRET donor domain”.
- an“acceptor domain” is any molecule that is capable of accepting energy emitted as a result of the activity of the donor domain.
- the acceptor domain can be a protein or non-protein acceptor domain.
- the acceptor domain (also referred to herein as “acceptor molecule”) is a fluorescent acceptor domain.
- fluorescent acceptor domain also referred herein to as “fluorescent acceptor molecule” refers to any compound which can accept energy emitted as a result of the activity of a donor domain, and re-emit it as light energy.
- the fluorescent acceptor domain can be a protein or non-protein fluorescent acceptor domain.
- the acceptor domain is selected from the group consisting of protein, small organic molecule, rare earth element chelate and quantum dot.
- Preferred acceptor domains are proteins.
- the acceptor domain is not a small organic molecule, rare earth element chelate or quantum dot.
- the acceptor domain is not a small organic molecule.
- the acceptor domain is not a rare earth element chelate.
- the acceptor domain is not a quantum dot.
- the fluorescent acceptor domain is a fluorescent protein.
- a fluorescent protein is a group of fluorophores that includes the green fluorescent protein from the jellyfish Aequorea victoria and numerous other variants (GFPs) arising from the application of molecular biology, for example mutagenesis and chimeric protein technologies (Tsien, 1998). GFPs are classified based on the distinctive component of their chromophores, each class having distinct excitation and emission wavelengths: class 1, wild-type mixture of neutral phenol and anionic phenolate: class 2, phenolate anion: class 3, neutral phenol: class 4, phenolate anion with stacked s-electron system: class 5, indole: class 6, imidazole: and class 7, phenyl.
- a naturally occurring acceptor molecule which has been mutated (variants) can also be useful for the present invention.
- One example of an engineered system which is suitable for BRET is a Renilla luciferase and enhanced yellow mutant of GFP (EYFP) pairing which do not directly interact to a significant degree with one another alone in the absence of a mediating protein(s) (in this case, the G protein coupled receptor) (Xu et al., 1999).
- Examples include, but are not limited to, green fluorescent protein (GFP), blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), superfolder GFP, Azami green, mWasabi, TagGFP, Turbo GFP, AcGFP, ZsGreen, T-Sapphire, enhanced CFP (ECFP), CyPET, AmCyanl, Midori-Ishi green, TagCFP, mTFPl (Teal), enhanced YFP (EYFP), GFPS65T, Emerald, Venus, mOrange, Topaz, mCitrine, YPet, TagYFP, PhiYFP, ZsYellow, mBanana, Kusabira Orange, Kusabira Orange2, mOrange, mOrange2, GFPuv, destabilised EGFP (dEGFP), destabilised ECFP (dECFP), destabilised EYFP (dEY
- the acceptor domain is a non-protein acceptor domain.
- the non-protein acceptor domain can be a fluorescent acceptor domain or a quencher.
- quencher refers to any compound which can accept energy emitted as a result of the activity of the donor domain, without re-emitting it as light energy.
- a non-fluorescent acceptor can be a quencher.
- the acceptor domain is selected from the group consisting of Alexa Fluor dye, Bodipy dye, Cy dye, fluorescein, dansyl, umbelliferone, Marina Blue, Cascade Blue, Cascade Yellow, Pacific Blue, Oregon Green, Tetramethylrhodamine, Rhodamine, coumarin, boron-dip yrromethene (BODIPY), resorufin, Texas Red, rare earth element chelates, or any combination or derivatives thereof.
- derivatives include, but are not limited to, amine reactive derivatives, aldehyde/ketone reactive derivatives, cytosine reactive or sulfhydryl reactive derivatives.
- the acceptor domain is fluorescein or a derivative thereof.
- Suitable derivatives include, but are not limited to, amine-reactive fluorescein derivatives, fluorescein isothiocyanate (FITC), NHS -fluorescein, NHS-LC-fluorescein, sulfhydryl-reactive fluorescein derivatives, 5-(and 6)-iodoacetamido-fluorescein, fluorescein-5-maleimide, fluorescein-6-maleimide, SAMSA-fluorescein, aldehyde/ketone and cytosine reactive fluorescein derivatives, fluorescein-5- thiosemicarbazide and 5-(((2-(carbohydrazine)methyl)thio) acetyl)-aminofluorescein.
- FITC fluorescein isothiocyanate
- NHS-fluorescein NHS-LC-fluorescein
- R2 is a fluorescein-5-maleimide derivative.
- the acceptor domain is rhodamine or a derivative thereof. Suitable derivatives include, but are not limited to, amine -reactive rhodamine derivatives, tetramethylrhodamine-5-(and 6)-isothiocyanate, NHS- rhodamine, LissamineTM rhodamine B sulfonyl chloride, LissamineTM rhodamine B sulfonyl hydrazine, sulphydryl-reactive rhodamine derivatives, tetramethylrhodamine-5-(and 6)- iodoacetamide, aldehyde/ketone and cytosine reactive rhodamine derivatives, Texas red hydrazine and texas red sulfonyl chloride.
- R2 is coumarin or a derivative thereof.
- Suitable derivatives include, but are not limited to, amine-reactive coumarin derivatives, AMCA, AMCA-NHS, AMCA-sulfo-NHS, sulphydryl-reactive coumarin derivatives, AMCA-HPDP, DCIA, aldehyde and ketone reactive coumarin derivatives and AMCA-hydrazide.
- the acceptor domain is boron-dipyrromethene (BODIPY) or a derivative thereof.
- Suitable derivatives include, but are not limited to, amine-reactive boron-dipyrromethene dyes, BODIPY FL C3-SE, BODIPY 530/550 C3, BODIPY 530/550 C3-SE, BODIPY 530/550 C3-hydrazide, BODIPY 493/503 C3-hydrazide, BODIPY FL C3-hydrazide, sulphydryl-reactive boron-dipyrromethene dyes, BODIPY FL 1A, BOPDIY 530/550 1A, Br-BOPDIPY 493/503 and aldehyde and ketone reactive boron-dipyrromethene dyes.
- the acceptor domain is Cy (cyanine) dye or a derivative thereof.
- Suitable derivatives include, but are not limited to, amine reactive cyanine dyes, thiol-reactive cyanine dyes and carbonyl-reactive cyanine dyes.
- the acceptor domain is a quencher. Any suitable quencher can be used.
- the acceptor domain is selected from the group consisting of DABCYL [4-((4-(Dimethylamino) phenyl)azo)benzoic acid], DABSYL (Dimethylaminoazosulfonic acid), metal nanoparticles such as gold and silver, black hole quenchers (BHQ), QSY dyes and QXL quenchers.
- R 2 is selected from the group consisting of DABCYL [4-((4- (Dimethylamino) phenyl)azo)benzoic acid], DABSYL (Dimethylaminoazosulfonic acid), black hole quenchers (BHQ), QSY dyes and QXL quenchers.
- the acceptor domain is a quantum dot.
- a “quantum dot” is a semiconductor composed of atoms from groups II- VI or III-V elements of the periodic table (e.g., CdSe, CdTe and InP). Quantum dots of the same material, but with different sizes, can emit light of different colours. Their brightness is attributed to the quantization of energy levels due to confinement of an electron in all three spatial dimensions. In a bulk semiconductor, an electron-hole pair is bound within the Bohr exciton radius, which is characteristic for each type of semiconductor. A quantum dot is smaller than the Bohr exciton radius, which causes the appearance of discrete energy levels.
- the band gap, DE, between the valance and conduction band of the semiconductor is a function of the nanocrystal's size and shape.
- quantum dots Compared to traditional organic fluorophores, quantum dots have slightly lower luminescence quantum yields but much larger absorption cross-sections and very low rates of photobleaching. Molar extinction coefficients of quantum dots are about 105 - 106 M-l cm-1, which is 10-100 times larger than dyes.
- quantum yield refers to a measure of final emission of original energy donation. Any quantum dot suitable for the purpose can be used.
- the optical properties of quantum dots can be manipulated by synthesizing a shell. Typically, the shell is a stabilizing shell.
- Such quantum dots are known as core-shell quantum dots and include but are not limited to CdSe/ZnS, InP/ZnS, InP/CdSe.
- Core/shell quantum dots have higher band gap shells around their lower band gap cores, which emit light without any absorption by the shell. The shell passivates surface nonradiative emission from the core thereby enhancing the photoluminescence quantum yield and preventing natural degradation.
- the shell of type I quantum dots (such as, CdSe/ZnS) has a higher energy conduction band and a lower energy valance band than that of the core, resulting in confinement of both electron and hole in the core.
- the conduction and valance bands of the shell of type II quantum dots are either both lower or both higher in energy than those of the core.
- type II quantum dots behave as indirect semiconductors near band edges and therefore, have an absorption tail into the red and near infrared.
- Alloyed semiconductor quantum dots can also be used, although types I and II are preferred.
- the alloy composition and internal structure which can be varied, permits tuning the optical properties without changing the particles' size.
- quantum dots are selected from the group consisting of CdSe/ZnS core/shell quantum dots, CdTe/CdSe core/shell quantum dots, CdSe/ZnTe core/shell quantum dots, and alloyed semiconductor quantum dots (e.g., CdSeTe).
- quantum dots can be stabilized or unstabilized by techniques known to the person skilled in the art.
- first component of the CRET pair and the second component of the CRET pair form a CRET pair.
- CRET pair is used to refer to a group of molecules that participate in energy transfer.
- the first component of the CRET pair comprises a BRET donor domain and second component of the CRET pair comprises a BRET acceptor domain.
- the first component of the CRET pair comprises a BRET acceptor domain and second component of the CRET pair comprises a BRET donor domain. Any number of donor- acceptor combinations can be used.
- the donor- acceptor combination should be capable of serving as a CRET pair (for example, a BRET pair).
- the separation and relative orientation of the donor domain and the acceptor domain, when the labelled antigen is bound to the antibody or antibody-like domain is within ⁇ 50% of the Forster distance.
- the term“the separation and relative orientation of the donor domain and the acceptor domain, when the labelled antigen is bound to the antibody or antibody-like domain” refers to the steady state CRET measurements which can be carried out within a range of ⁇ 50% of Ro. This phrase encompasses an efficiency of luminescence energy transfer (also referred to herein as“efficiency of energy transfer” ) from the donor domain to the acceptor domain in the range of 10- 90%.
- the term“efficiency of energy transfer” means the fraction of energy that is non radiatively transferred from an excited state donor to a ground state acceptor per donor excitation event.
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75% when the labelled antigen is bound to the antibody or the antibody-like molecule.
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 15 to 75%, 20 to 75%, 25 to 75%, 30 to 75%, 35 to
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 70%, 10 to 65%, 10 to 60%, 10 to 55%, 10 to 50%, 10 to 45%, 10 to
- the Forster distance of the chemiluminescent donor domain and the acceptor domain is at least 4 nm, is at least 5.6 nm, or is at least 6 nm. In some embodiments, the Forster distance is less than 12 nm, less than 11 nm, less than 10 nm or less than 9 nm. In some embodiments, the Forster distance of the donor domain and the acceptor domain is between about 4 nm and about 11 nm, is between about 5.6 nm and about 11 nm or is between about 7 nm and about 11 nm. In some embodiments, the Forster distance of the CRET pair is between about 4 nm and about 18 nm, or is between about 6 nm and about 12 nm, or is between about 7.5 nm and 10.5 nm.
- a criterion which should be considered in determining suitable pairings is the relative emission/fluorescence spectrum of the acceptor molecule compared to that of the donor.
- the emission spectrum of the donor should overlap with the absorbance spectrum of the acceptor molecule such that the light energy from the donor emission is at a wavelength that is able to excite the acceptor molecule and thereby promote acceptor molecule fluorescence when the two molecules are in a proper proximity and orientation with respect to one another.
- Renilla luciferase/EGFP pairing is not as good as a Renilla luciferase/EYEF pairing based on observable emission spectral peaks (Xu et al., 1999; Wang et al., 1997 in Bioluminescence and Chemiluminescence: Molecular Reporting with Photons, eds. Hastings et al., (Wiley, New York), pp. 419-422).
- protein fusions for example are prepared containing the selected donor and acceptor domains and are tested, in the presence of an appropriate substrate if required.
- the donor and acceptor domains do not spuriously associate with each other.
- this can be accomplished by separate co-expression of the first component of the CRET pair and the second component of the CRET pair in the same cells and then monitoring the luminescence spectrum in order to determine if energy transfer occurs. This may be achieved, for example, using the method of Xu et al. (1999).
- the selected first component of the CRET pair and the second component of the CRET pair form a suitable CRET pair if little or no CRET is observed.
- the donor emission can be manipulated by modifications to the substrate. In the case of Renilla luciferases the substrate is coelenterazine.
- the rationale behind altering the donor emission is to improve the resolution between donor emission and acceptor emissions.
- the original BRET system uses the Renilla luciferase as donor, EYFP (or Topaz) as the acceptor and coelenterazine h derivative as the substrate. These components when combined in a BRET assay, generate light in the 475-480 nm range for the bioluminescent protein and the 525-530 nm range for the acceptor molecule, giving a spectral resolution of 45-55 nm.
- Renilla luciferase generates a broad emission peak overlapping substantially the GFP emission, which in turn contributes to decrease the signal to noise of the system.
- One BRET system for use in the present invention has coel400a as the Renilla luciferase substrate and provides broad spectral resolution between donor and acceptor emission wavelengths ( ⁇ 105nm). Renilla luciferase with coeMOOa generates light between 390-400 nm and a GFP derivative (GFP 2 ) was prepared which absorbs light in this range and re-emits light at 505-508 nm.
- this BRET system provides an excellent biological tool to monitor binding of a carbohydrate to the sensors of the present application.
- smaller Stokes shift BRET systems would also allow sensitive measurement of carbohydrates.
- coelenterazine derivatives are known in the art, including coel400a, that generate light at various wavelengths (distinct from that generated by the wild type coelenterazine) as a result of Renilla luciferase activity.
- coel400a that generate light at various wavelengths (distinct from that generated by the wild type coelenterazine) as a result of Renilla luciferase activity.
- a worker skilled in the art would appreciate that because the light emission peak of the donor has changed, it is necessary to select an acceptor molecule which will absorb light at this wavelength and thereby permit efficient energy transfer. This can be done, for example by altering a GFP class 4 such that it becomes a class 3 or 1 GFP.
- Spectral overlapping between light emission of the donor and the light absorption peak of the acceptor is one condition among others for an efficient energy transfer.
- Class 3 and 1 GFPs are known to absorb light at 400 nm and re-emit between 505-511 nm.
- a CRET pair (also referred to herein as an immunosensor) comprising:
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair;
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%.
- the components of the CRET pair are as defined herein.
- the preferred CRET pair comprises RLuc8 and GFP 2 .
- the antibody or antibody-like molecule is attached to RLuc8 and the labelled antigen is attached to GFP 2 .
- the antibody or antibody-like molecule is attached to GFP 2 and the labelled antigen is attached to RLuc8. Detecting an Analyte
- the labelled antigen in the absence of analyte, is able to bind to the antibody or antibody-like molecule bringing the first and second component of the CRET pair together resulting in CRET between the two components in the presence of a substrate.
- the analyte competes with the labelled antigen for binding to the antibody or antibody-like molecule resulting in a reduction in CRET between the two components in the presence of a substrate.
- binding of an analyte to the antibody or antibody-like molecule of the present disclosure alters the spatial location and/or dipole orientation of the first component of the CRET pair relative to the second component of the CRET pair.
- the term“spatial location” refers to the three dimensional positioning of the donor relative to the acceptor molecule which changes as a result of the analyte binding or releasing from the antibody or antibody-like molecule.
- dipole orientation refers to the direction in three- dimensional space of the dipole moment associated either with the donor and/or the acceptor molecule relative their orientation in three-dimensional space.
- the dipole moment is a consequence of a variation in electrical charge over a molecule.
- the efficiency of energy transfer can be determined ratiometrically (for example, CRET ratio, preferably BRET ratio).
- CRET ratio for example, CRET ratio, preferably BRET ratio.
- BRET BRET
- binding of an analyte to the antibody or antibody-like molecule of the present disclosure is indicated by a reduction in the BRET ratio.
- a reduction in the efficiency of energy transfer between the first and second components of the CRET pair is indicated by a reduction in the BRET ratio.
- the energy transfer occurring between the first component of the CRET pair (for example, a bioluminescent protein) and the second component of a CRET pair (for example, an acceptor molecule) is presented as calculated ratios from the emissions measured using optical filters (one for the acceptor molecule emission and the other for the bioluminescent protein emission) that select specific wavelengths (see equation 1).
- E a /E d BRET ratio (1)
- E a is defined as the acceptor molecule emission intensity (emission light is selected using a specific filter adapted for the emission of the acceptor)
- E d is defined as the bioluminescent protein emission intensity (emission light is selected using a specific filter adapted for the emission of the bioluminescent protein).
- optical filters may be any type of filter that permits wavelength discrimination suitable for BRET.
- optical filters used in accordance with the present invention can be interference filters, long pass filters, short pass filters, etc.
- Intensities (usually in counts per second (CPS) or relative luminescence units (RLU)) of the wavelengths passing through filters can be quantified using either a photo -multiplier tube (PMT), photodiode, including a cascade photodiode, photodiode array or a sensitive camera such as a charge coupled device (CCD) camera.
- the quantified signals are subsequently used to calculate BRET ratios and represent energy transfer efficiency.
- the BRET ratio increases with increasing intensity of the acceptor emission.
- a ratio of the acceptor emission intensity over the donor emission intensity is determined (see equation 1), which is a number expressed in arbitrary units that reflects energy transfer efficiency. The ratio increases with an increase of energy transfer efficiency (see Xu et al., 1999).
- Energy transfer efficiencies can also be represented using the inverse ratio of donor emission intensity over acceptor emission intensity (see equation 2). In this case, ratios decrease with increasing energy transfer efficiency.
- the emission intensities Prior to performing this calculation the emission intensities are corrected for the presence of background light and auto-luminescence of the substrate. This correction is generally made by subtracting the emission intensity, measured at the appropriate wavelength, from a control sample containing the substrate but no bioluminescent protein, acceptor molecule or polypeptide of the invention.
- the light intensity of the bioluminescent protein and acceptor molecule emission can also be quantified using a monochromator-based instrument such as a spectrofluorometer, a charged coupled device (CCD) camera or a diode array detector.
- a monochromator-based instrument such as a spectrofluorometer, a charged coupled device (CCD) camera or a diode array detector.
- CCD charged coupled device
- the emission scan is performed such that both bioluminescent protein and acceptor molecule emission peaks are detected upon addition of the substrate.
- the areas under the peaks represent the relative light intensities and are used to calculate the ratios, as outlined above.
- Any instrument capable of measuring lights for the bioluminescent protein and acceptor molecule from the same sample can be used to monitor the BRET system of the present invention.
- the acceptor molecule emission alone is suitable for effective detection and/or quantification of BRET.
- the energy transfer efficiency is represented using only the acceptor emission intensity. It would be readily apparent to one skilled in the art that in order to measure energy transfer, one can use the acceptor emission intensity without making any ratio calculation. This is due to the fact that ideally the acceptor molecule will emit light only if it absorbs the light transferred from the bioluminescent protein. In this case only one light filter is necessary.
- the bioluminescent protein emission alone is suitable for effective detection and/or quantification of BRET.
- the energy transfer efficiency is calculated using only the bioluminescent protein emission intensity. It would be readily apparent to one skilled in the art that in order to measure energy transfer, one can use the donor emission intensity without making any ratio calculation. This is due to the fact that as the acceptor molecule absorbs the light transferred from the bioluminescent protein there is a corresponding decrease in detectable emission from the bioluminescent protein. In this case only one light filter is necessary.
- the energy transfer efficiency is represented using a ratiometric measurement which only requires one optical filter for the measurement.
- E a and E d are as defined above and E 0 is defined as the emission intensity for all wavelengths combined (open spectrum).
- equations 1 through 4 can be derived from equations 1 through 4.
- one such derivative involves correcting for background light present at the emission wavelength for bioluminescent protein and/or acceptor molecule.
- the BRETCount instrument is a modified TopCount, wherein the TopCount is a microtiterplate scintillation and luminescence counter sold by Packard Instrument (Meriden, CT). Unlike classical counters which utilise two photomultiplier tubes (PMTs) in coincidence to eliminate background noise, TopCount employs single- PMT technology and time -resolved pulse counting for noise reduction to allow counting in standard opaque microtiter plates. The use of opaque microtiter plates can reduce optical crosstalk to negligible level. TopCount comes in various formats, including 1, 2, 6 and 12 detectors (PMTs), which allow simultaneous reading of 1, 2, 6 or 12 samples, respectively.
- PMTs photomultiplier tubes
- BRET Beside the BRETCount, other commercially available instruments are capable of performing BRET: the Victor 2 (Wallac, Finland (Perkin Elmer Life Sciences)) and the Fusion (Packard Instrument, Meriden).
- BRET can be performed using readers that can detect at least the acceptor molecule emission and preferably two wavelengths (for the acceptor molecule and the bioluminescent protein) or more.
- BRET is a ratiometric technique which can eliminate data variability caused by fluctuations in light output due to variations in assay volume, assay conditions and signal decay across different wells in a plate.
- RET -based reactions are homogeneous, generally occurring in solution without solid-phase attachment. This allows for detection of analytes in different forms such as liquid, gas and even particulates without separation.
- the antibody, antibody-like molecule, antigen, labelled antigen, linker, first component of the CRET pair and/or second component of the CRET pair can consist of or comprise a polypeptide.
- the terms“polypeptide” and“protein“ are generally used interchangeably and refer to a single polypeptide chain which may or may not be modified by addition of non-amino acid groups or other component such as a sugar moiety.
- the terms “proteins” and “polypeptides” as used herein also include variants, mutants, modifications, analogous and/or derivatives of the polypeptides of the disclosure as described herein.
- the antibody or antibody-like molecules defined herein can comprise functional variants, mutants, modifications, analogous and/or derivatives thereof. The variants, mutants, modifications, analogous and/or derivatives thereof retain the ability to bind specifically to the antigen.
- Polypeptide components can be produced in a variety of ways, including production and recovery of natural polypeptides, production and recovery of recombinant polypeptides, and chemical synthesis of the polypeptides.
- an isolated polypeptide component e.g. an antibody
- an isolated polypeptide component is produced by culturing a cell capable of expressing the polypeptide under conditions effective to produce the polypeptide, and recovering the polypeptide.
- one or more of the polypeptide components can be purchased from a commercial supplier.
- the antibody or antibody-like molecule can be purchased from a commercial supplier and used to form the immunosensor of the present disclosure. Accordingly, any commercially available antibody or antibody-like molecule is suitable for use in the present disclosure.
- the antibody or antibody-like molecule can be produced or obtained from a commercial supplier and then covalently attached, optionally via a linker, the first component of the CRET pair to form an antibody conjugate.
- a capable cell has been transformed with a polynucleotide encoding a polypeptide component.
- “transformed” or“transformation” is the acquisition of new genes in a cell by the incorporation of a polynucleotide.
- polynucleotide is used interchangeably herein with the term “nucleic acid”.
- Polynucleotide refers to an oligonucleotide, nucleic acid molecule or any fragment thereof. It may be DNA or RNA of genomic or synthetic origin, double- stranded or single-stranded. Suitable polynucleotides may also encode secretory signals such as a signal peptide (i.e., signal segment nucleic acid sequences) to enable an expressed polypeptide to be secreted from the cell that produces the polypeptide.
- signal peptide i.e., signal segment nucleic acid sequences
- Suitable signal segments include tissue plasminogen activator (t-PA), interferon, interleukin, growth hormone, viral envelope glycoprotein signal segments, Nicotiana nectarin signal peptide (US 5,939,288), tobacco extensin signal, the soy oleosin oil body binding protein signal, Arabidopsis thaliana vacuolar basic chitinase signal peptide, as well as native signal sequences.
- t-PA tissue plasminogen activator
- interferon interleukin
- interleukin growth hormone
- viral envelope glycoprotein signal segments include t-PA
- the polynucleotide may encode intervening and/or untranslated sequences.
- purification tags include, but are not limited to, hexahistidine, GST, Trx, Calmodulin Binding Peptide, intein-chitin binding domain, Strep-tag, NusA, SUMO and MBP and epitope tags such as HA, c-myc, FLAG, Halotag and biotin.
- Suitable polynucleotides may also encode polypeptide sequences which comprise protease cleavage sites to facilitate removal of the purification and/or identification tags. Suitable protease cleavage sites are known in the art and include the TEV, thrombin and SUMO protease cleavage sites.
- Mutant (altered) polypeptides can be prepared using any technique known in the art.
- a polynucleotide encoding an enzyme encompassed by the present disclosure can be subjected to in vitro mutagenesis.
- in vitro mutagenesis techniques include sub-cloning the polynucleotide into a suitable vector, transforming the vector into a“mutator” strain such as the E. coli XL-1 red (Stratagene) and propagating the transformed bacteria for a suitable number of generations.
- the polynucleotides of the disclosure are subjected to DNA shuffling techniques as broadly described by Harayama (1998). Products derived from mutated/altered DNA can readily be screened using techniques described herein to determine if they can be used in an antibody conjugate/labelled analyte of the present disclosure.
- the location of the mutation site and the nature of the mutation will depend on characteristic(s) to be modified.
- the sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting other residues adjacent to the located site.
- Amino acid sequence deletions generally range from about 1 to 15 residues, more preferably about 1 to 10 residues and typically about 1 to 5 contiguous residues.
- Substitution mutants have at least one amino acid residue in the polypeptide molecule removed and a different residue inserted in its place.
- the sites of greatest interest for substitutional mutagenesis include sites identified as important for function. Other sites of interest are those in which particular residues obtained from various strains or species are identical. These positions may be important for biological activity. These sites, especially those falling within a sequence of at least three other identically conserved sites, are preferably substituted in a relatively conservative manner. Such conservative substitutions are known to the person skilled in the art.
- Polynucleotides can be expressed using a suitable recombinant expression vector.
- a polynucleotide encoding the above referenced polypeptide components can be operatively linked to an expression vector.
- the phrase“operatively linked” refers to insertion of a polynucleotide molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell.
- the phrase refers to the functional relationship of a transcriptional regulatory element to a transcribed sequence.
- a promoter is operably linked to a coding sequence, if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell.
- an expression vector is a DNA or RNA vector that is capable of transforming a host cell and of effecting expression of a specified polynucleotide molecule.
- the expression vector is also capable of replicating within the host cell.
- Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids.
- Suitable expression vectors include any vectors that function (i.e., direct gene expression) in a recombinant cell, including in bacterial, fungal, endoparasite, arthropod, animal, and plant cells.
- Vectors of the disclosure can also be used to produce a polypeptide component(s) in a cell-free expression system, such systems are well known in the art.
- Suitable vectors can contain heterologous polynucleotide sequences, that is polynucleotide sequences that are not naturally found adjacent to polynucleotide encoding the above referenced polypeptides.
- the vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a transposon (such as described in US 5,792,294), a virus or a plasmid.
- Suitable, expression vectors can also contain regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of specified polynucleotide molecules.
- Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences.
- a variety of suitable transcription control sequences are known to those skilled in the art.
- transcription control sequences which function in bacterial, yeast, arthropod, plant or mammalian cells, such as, but not limited to, tac, lac, trp, trc, oxy-pro, omp/lpp, rmB, bacteriophage lambda, bacteriophage T7, T71ac, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alphamating factor, Pichia alcohol oxidase, alphavirus subgenomic promoters (such as Sindbis virus subgenomic promoters), antibiotic resistance gene, baculovirus, Heliothis zea insect virus, vaccinia virus, herpesvirus, raccoon poxvirus, other poxvirus, adenovirus, cytomegalovirus (such as intermediate early promoters), simian virus 40, retrovirus, actin, retroviral long terminal ⁇ repeat, Rous sarcoma virus, heat shock,
- a host cell suitable for preparing the antibody, antibody-like molecule, linker, antigen, first component of the CRET pair and/or second component of the CRET pair of the present disclosure includes a recombinant cell transformed with one or more polynucleotides that encode the antibody, antibody-like molecule, linker, antigen, first component of the CRET pair and/or second component of the CRET pair, or progeny cells thereof. Transformation of a polynucleotide molecule into a cell can be accomplished by any method by which a polynucleotide molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. Transformed polynucleotide molecules can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained.
- Suitable host cells to transform include any cell that can ,be transformed with a polynucleotide encoding the antibody, antibody-like molecule, linker, antigen, first component of the CRET pair and/or second component of the CRET pair.
- Suitable host cells can be endogenously (i.e., naturally) capable of producing the antibody, antibody like molecule, linker, antigen, first component of the CRET pair and/or second component of the CRET pair or can be capable of producing such polypeptides after being transformed with at least one polynucleotide molecule encoding the component(s).
- Suitable host cells include bacterial, fungal (including yeast), parasite, arthropod, animal and plant cells.
- host cells examples include Salmonella , Escherichia, Bacillus, Listeria, Saccharomyces, Spodoptera., Mycobacteria, Trichoplusia, BHK (baby hamster kidney) cells, MDCK cells, CRFK cells, CV-1 cells, COS (e.g., COS-7) cells, CHO cells and Vero cells.
- Further examples of host cells are E. coli, including E. coli K-12 derivatives; Salmonella typhv, Salmonella typhimurium, including attenuated strains; Spodoptera frugiperda ; Trichoplusia nr, and non- tumorigenic mouse myoblast GS cells (e.g., ATCC CRL 1246).
- Suitable mammalian host cells include other kidney cell lines, other fibroblast cell lines (e.g., human, murine or chicken embryo fibroblast cell lines), myeloma cell lines, Chinese hamster ovary cells, mouse NIH/3T3 cells, LMTK cells and/or HeLa cells.
- fibroblast cell lines e.g., human, murine or chicken embryo fibroblast cell lines
- myeloma cell lines e.g., Chinese hamster ovary cells, mouse NIH/3T3 cells, LMTK cells and/or HeLa cells.
- Recombinant techniques useful for increasing the expression of polynucleotide molecules of the present disclosure include, but are not limited to, operatively linking polynucleotide molecules to high-copy number plasmids, integration of the polynucleotide molecule into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites; Shine-Dalgamo sequences), modification of polynucleotide molecules of the present disclosure to correspond to the codon usage of the host cell, and the deletion of sequences that destabilise transcripts.
- transcription control signals e.g., promoters, operators, enhancers
- translational control signals e.g., ribosome binding sites; Shine-Dalgamo sequences
- Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit polypeptide production.
- An effective medium refers to any medium in which a cell is cultured to produce a polypeptide of the present disclosure.
- Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins.
- Cells can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions ⁇ are within the expertise of one of ordinary skill in the art.
- antibody/antibody-like molecules, labelled antigens, methods, kits and compositions as defined herein can be used for detecting an analyte in a sample. Accordingly, antibody/antibody-like molecules, labelled antigens, such as those described herein, enable the detection of a plethora of antigens including disease biomarkers, pathogens, drugs, environmental contaminants, allergens and food adulterants, for POC diagnostics, therapeutic drug monitoring and companion diagnostics, clinical pharmokinetics, veterinary diagnostics, food analysis, environmental monitoring, defence and security.
- the analyte may be any molecule which can be bound by an antibody or antibody-like molecule or for which an antibody or antibody-like molecule can be developed.
- the analyte is selected from the group consisting of small organic molecule, drug, drug metabolite, antibiotic, hormone, allergen, peptide, protein, naturally occurring antibody, sugar, lipid or nucleic acid.
- the term“analyte” refers to serum proteins, cholesterol, polysaccharides, nucleic acids, drugs and drug metabolites, etc., found in bodily fluids and tissues of the body.
- the analyte is any biological analyte, marker, gene, protein, metabolite, or hormone or combination therein indicative of a biological state desirable for analysis to determine a physical state or condition.
- the analyte is a naturally occurring antibody.
- the term “small organic molecule” refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 25 daltons and less than about 3000 daltons, preferably less than about 2500 daltons, more preferably less than about 2000 daltons, preferably between about 100 to about 1000 daltons, more preferably between about 200 to about 500 daltons.
- the small organic molecule is a small organic molecule with antimicrobial, antibiotic, analgesic, or other biological activity.
- the small organic molecule is triclocarban (TCC).
- TCC triclocarban
- the small organic molecule is ampicillin.
- the analyte is an allergen contained in a food product.
- Allergens include, but are not limited to egg, dairy products, meat, fish, crustaceans for example prawns, crabs, lobster, crayfish, cereals containing gluten (for example wheat (such as spelt and khorasan wheat), rye, barley and oats), soybeans, beans, peanuts, nuts for example almonds, hazelnuts, walnuts, cashews, pecan nuts, Brazil nuts, pistachio nuts, macadamia (or Queensland) nuts, celery (including celeriac), mustard, sesame, sulphur dioxide/sulphites, lupin, molluscs like, mussels, whelks, oysters, snails and squid, seeds, fruits.
- the analyte is casein, alpha-lactoglobulin, alpha- lactoglobulin, ovalbumin, ovomucoid, gliadin, Arahl, Arah2.
- the antigen may be any of the epitopes and/or proteins identified in“Scientific Opinion on the evaluation of allergenic foods and food ingredients for labelling purposes”. EFSA Panel on Dietetic Products, Nutrition and Allergies. EFSA Journal 2014; 12(11): 3894.
- the antigen may be any of the epitopes and/or proteins listed in Table 3.
- Table 3 Exemplary epitopes and/or proteins.
- the food product may be any product intended for consumption that is suspected of containing an allergen.
- Other examples in food analysis include the detection of contaminants and adulterants in food products, for example, aflatoxins, other mycotoxins, natural or artificial hormones (including growth promoting hormones), antibiotics, pesticides, marine toxins and bacteria.
- the analyte is melamine, cyanuric acid or any other nitrogenous compound used to fraudulently increase the nitrogen content of dairy product and the antibody or antibody-like molecule is an antibody specific for melamine, cyanuric acid or the other nitrogenous compound used to fraudulently increase the nitrogen content of dairy product.
- the analyte is a coagulase enzyme from Staphylococcus aureus and the antibody or antibody-like molecule is an antibody specific for coagulase enzyme from S. aureus.
- the analyte may be a naturally occurring antibody which competes with the antibody or antibody-like molecule defined herein for binding to the labelled antigen.
- a“naturally occurring antibody” refers to an antibody generated in a subject, for example, during an immune response to an infection with a microorganism, such as a bacterium, virus, fungus, mycoplasma or parasite or an immunisation.
- binding of the labelled antigen to the naturally occurring antibody results in a reduction the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair.
- the analyte is a naturally occurring antibody raised in a subject in response to an immunistaion.
- the analyte is a naturally occurring antibody raised in a subject in reponse to an infection with a microorganism.
- the subject is a human or other animal.
- the subject can be selected from the group consisting of humans, beef cattle, dairy cattle, sheep, goats, horses, swine, buffalos and camelids (for example, camels and llamas).
- the subject is a human.
- the subject is livestock.
- livestock refers to animals, such as beef cattle, dairy cattle, sheep, goats, horses, swine, buffalos and camels raised for food or for the production of food for home use or for large scale production and or for profit, particularly on a farm.
- the antibody/antibody-like molecules, labelled antigens, methods, kits and compositions as defined herein can be used to qualitatively and/or quantitatively “detect” analytes.
- the analytes are present in micromolar to nanomolar concentrations.
- sample can be any substance or composition that has the potential to contain the analyte of interest.
- the sample is air, liquid, biological material or soil.
- the sample is selected from the group consisting of a food product or an extract thereof, soil or an extract thereof, biological materials or an extract thereof and the like.
- the sample may be obtained directly from the environment or source, or may be extracted and/or at least partially purified by a suitable procedure before a method of the invention is performed.
- the sample comprises a biological material.
- biological materials is defined broadly and includes any material derived in whole or in part from an organism. Biological materials include, but are not limited to, bodily fluids, cells, soft tissues (such as connective and non-connective tissue) and hard tissues (such as bone and cartilage).
- the bodily fluids are blood, serum, sputum, mucus, pus, peritoneal fluid, urine or other bodily fluids.
- such materials may have been harvested from a living organism and then subjected to further processing and/or chemical treatment.
- the sensor is not used to detect an analyte within a living cell. In some embodiments, the sensor is used ex vivo.
- the sample comprises a food product.
- food product is defined broadly and includes a composition that is intended to be ingested by an animal, including mammals, for nutritional purposes, whether eaten or drunk.
- the sample is a food product that is or has the potential to be contaminated with a toxin, allergen, adulterant and the like.
- the sample is an aqueous liquid.
- the sample includes but is not limited to, milk, fruit juices, other beverages and bodily fluids including blood serum.
- the immunosensors of the present invention can also be multiplexed.
- the term“immunosensor” refers to the combination of antibody or antibody-like molecule attached to a first component of the CRET pair and corresponding labelled antigen attached to a second component of a CRET pair.
- an“immunosensor” can also be referred to as a“CRET pair”.
- two or more different antibodies or antibody-like molecules with corresponding labelled antigens may be provided which detect a different analyte.
- an antibody or antibody-like molecule of the present invention that detects one allergen can be multiplexed with an antibody or antibody-like molecule that detect another allergen.
- each different immunosensor may include a different donor and/or acceptor domains such that they emit at different wavelengths to enable the detection and quantification of different analytes.
- each different immunosensor may comprise the same donor and/or acceptor molecule.
- a single fluidic detection chamber is used.
- a multi-channel detection device may be used. Compositions, Kits, Methods and Uses
- the antibody or antibody-like molecules and/or labelled analytes described herein may be included in compositions for use in detecting analytes.
- the antibody or antibody-like molecules and/or labelled analytes described herein may be included in compositions for use in detecting analytes.
- a composition comprising an antibody or antibody-like molecule in accordance with the present invention and an acceptable carrier.
- a composition comprising an antibody or antibody-like molecule and a labelled analyte in accordance with the present invention and an acceptable carrier.
- a composition comprising labelled analyte in accordance with the present invention and an acceptable carrier.
- the term“acceptable carrier” includes any and all solids or solvents (such as phosphate buffered saline buffers, water, saline) dispersion media, coatings, and the like, compatible with the methods and uses of the present invention.
- the acceptable carriers must be“acceptable” in the sense of being compatible with the other ingredients of the composition, not damaging the analytes being tested for and not inhibiting specific binding of the analyte to the antibody or fragment thereof.
- suitable acceptable carriers are known in the art and are selected based on the end use application.
- the antibody or antibody-like molecules and/or labelled antigens of the present application can be used to detect the presence or absence of analyte in a sample, and if present may also be used to determine the amount of the analyte present in the sample. Therefore, in some embodiments there is provided a method for detecting an analyte in a sample, the method comprising
- CRET chemiluminescence resonance energy transfer
- a labelled antigen comprising an antigen capable of binding to the antibody or the antibody-like molecule attached to a second component of the CRET pair; wherein, when the labelled antigen is bound to the antibody or the antibody like molecule, the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%;
- the reduction in the efficiency of energy transfer between the first and second components of the CRET pair is observed in real time. In alternative embodiments, the reduction in the efficiency of energy transfer between the first and second components of the CRET pair is relative to the efficiency of energy transfer between the first and second components of the CRET pair in the absence of sample (for example, in the presence of a buffer control).
- the efficiency of energy transfer from the first component to the second component is in the range of 15 to 75%, 20 to 75%, 25 to 75%, 30 to 75%, 35 to 75%, 40 to 75%, 45 to 75%, 50 to 75%, 55 to 75%, 60 to 75%, or greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45% or greater than 50%, when the labelled antigen is bound to the antibody or antibody-like molecule. In some embodiments, the efficiency of energy transfer from the first component to the second component is in the range of 15 to 65% when the labelled antigen is bound to the antibody or antibody-like molecule.
- step (i) comprises
- step (i)(a)) there will be an increase in the efficiency of energy transfer between the first and second components of the CRET pair after contacting the resulting mixture with the labelled antigen (i.e. observed in real time). However, if an analyte of interest is present in the sample, there will be a reduction in the efficiency of energy transfer between the first and second components of the CRET pair relative to the efficiency of energy transfer between the first and second components of the CRET pair in the absence of the sample. Similarly, if the method is performed by contacting the sample with the antibody or antibody-like molecule and the labelled antigen at the same time (i.e. step (i)(c)) the efficiency of energy transfer between the first and second components of the CRET pair may not change in real time.
- step (i) is performed by first contacting the sample with the labelled antigen and then contacting the resulting mixture with the antibody or antibody-like molecule (i.e. step (i)(b)), a reduction in the efficiency of energy transfer between the first and second components of the CRET pair will be observed in real time if the analyte of interest is present in sample.
- step ii) comprises comparing the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair in the presence of sample to the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair in the absence of sample, wherein a reduction in the efficiency of energy transfer between the first and second components of the CRET pair in the presence of sample indicates that the analyte is present in the sample.
- step ii) comprises comparing the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair before the sample is added to the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair after the sample is added, wherein a reduction in the efficiency of energy transfer between the first and second components of the CRET pair in the presence of sample indicates that the analyte is present in the sample.
- step (i) further comprises contacting the sample with a substrate.
- the method does not require a secondary antibody.
- a secondary antibody is not required. This reduces the number of steps required in the assay and can reduce the time required to perform the method. In some embodiments, the method is performed in real time.
- determining if the spatial location and/or dipole orientation of the BRET donor domain relative to the acceptor domain has been altered in the presence of the sample comprises measuring the BRET ratio before and after addition of the sample.
- the method further comprises determining the concentration of the analyte in the sample.
- the concentration of an analyte in a sample can be determined by comparing the efficiency of energy transfer (for example, as represented by the BRET ratio) in the presence of sample with the efficiency of energy transfer at known concentrations of analyte, for example by constructing a standard curve.
- the methods of the present invention can be used to measure the concentration of an analyte in a sample at nanomolar or picomolar levels.
- At least 1 pM, at least 5 pM, at least 10 pM, at least 25 pM, at least 50 pM, at least 75 pM, at least 100 pM, at least 200 pM, at least 300 pM, at least 400 pM, at least 500 pM, at least 600 pM, at least 700 pM, at least 800 pM, at least 900 pM, at least 1 nM, at least 5 nM, at least 10 nM, at least 25 nM, at least 50 nM, at least 75 nM, at least 100 nM, at least 200 nM, at least 300 nM, at least 400 nM, at least 500 nM, at least 600 nM, at least 700 nM, at least 800 nM, at least 900 nM, of analyte can be detected.
- a method of detecting an analyte in a sample comprising
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to green fluorescent protein 2;
- step (i) further comprises contacting the sample with a substrate.
- a method of classifying a sample comprising
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair, d) a substrate of one of the first or second component of the CRET pair, wherein, when the labelled antigen is bound to the antibody or antibody-like molecule, the efficiency of energy transfer between the first component and the second component is in the range of 10 to 75%,
- the method above method can be used to classify a sample based on the analytes they contain. In some embodiments, the above method can be used to classify a sample based on the presence, absence or concentration of one or more analytes. In some embodiments, the above method comprises two or more different antibody or antibody-like molecules each of which binds a different analyte or range of analytes and two or more different labelled antigens, and step v) comprises classifying the sample based on the presence, absence or concentration of each of the analytes or range of analytes. In some embodiments, the sample is classified into two or more classes, for example safe or hazardous, contaminated or uncontaminated, authentic or fraudulent or low value/medium value/high value. In some embodiments, the method can be used to classify the sample in real time. In some embodiments, the sensor molecule is not fixed to the device. In some embodiments, the sensor molecule and substrate enter the device through different microchannels.
- the antibody or antibody-like molecules and labelled antigens described herein can also be used in methods for detecting naturally occurring antibodies. Therefore, in some embodiments there is provided a method of detecting a naturally occurring antibody in a sample, the method comprising
- CRET chemiluminescence resonance energy transfer
- a labelled antigen comprising an antigen capable of binding to the naturally occurring antibody attached to a second component of the CRET pair; wherein the antibody or antibody-like molecule attached to a first component of the CRET pair and the naturally occurring antibody are capable of binding to the labelled antigen;
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%;
- step (i) further comprises contacting the sample with a substrate.
- step (ii) comprises determining if the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair has been reduced in the presence of the sample.
- the CRET ratio may be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%. 45%, 50%, 55%. 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% in the presence of the sample.
- the CRET ratio is be reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% in the presence of sample.
- step (ii) comprises determining if the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair has been increased in the presence of the sample.
- step (i) comprises
- step (i) further comprises contacting the sample with a substrate.
- the efficiency of energy transfer from the first component to the second component is in the range of 15 to 75%, 20 to 75%, 25 to 75%, 30 to 75%, 35 to 75%, 40 to 75%, 45 to 75%, 50 to 75%, 55 to 75%, 60 to 75%, or greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45% or greater than 50%, when the labelled antigen is bound to the antibody or antibody-like molecule. In some embodiments, the efficiency of energy transfer from the first component to the second component is in the range of 15 to 65% when the labelled antigen is bound to the antibody or antibody-like molecule.
- the method further comprises determining the concentration of the naturally occurring antibody in the sample.
- the concentration of the naturally occurring antibody in a sample can be determined by comparing the efficiency of energy transfer (for example, as represented by the BRET ratio) in the presence of sample with the efficiency of energy transfer at known concentrations of naturally occurring antibody, for example by constructing a standard curve.
- the methods of the present invention can be used to measure the concentration of an analyte in a sample at nanomolar or picomolar levels.
- At least 1 pM, at least 5 pM, at least 10 pM, at least 25 pM, at least 50 pM, at least 75 pM, at least 100 pM, at least 200 pM, at least 300 pM, at least 400 pM, at least 500 pM, at least 600 pM, at least 700 pM, at least 800 pM, at least 900 pM, at least 1 nM, at least 5 nM, at least 10 nM, at least 25 nM, at least 50 nM, at least 75 nM, at least 100 nM, at least 200 nM, at least 300 nM, at least 400 nM, at least 500 nM, at least 600 nM, at least 700 nM, at least 800 nM, at least 900 nM, of analyte can be detected.
- the method can be used to detect and quantify seroconversion in a subject.
- seroconversion is intended to refer to the situation where an infection with a microorganism, such as a bacterium, virus, fungus, mycoplasma or parasite or an immunisation generates an immune response in a subject.
- Measurement of the immune response,“serology” is frequently used to determine the infection status, immune status or susceptibility to complications of the subject.
- the sample is serum or other biological fluids suspected of containing naturally antibodies
- kits which may include, but are not limited to, one or more of the following: an antibody or antibody-like molecule attached to a first component of a CRET system, a labelled antigen attached to a second component of a CRET system, a substrate, a test standard, and directions (written instructions for their use).
- the components listed above can be tailored to the particular analyte to be monitored.
- the kit can further include appropriate buffers and reagents known in the art performing the methods described herein.
- the methods of the present invention can be performed on any system suitable for measuring energy transfer between a CRET pair.
- the methods of the present invention can be performed in a batch (for example batch format using a plate reader) or flow format.
- the methods of the present invention can be performed in a microplate format using a microplate reader equipped with the appropriate filters.
- the methods of the present invention can also be performed on a microfluidic device, such as described in WO2013/ 155553.
- the methods of the present invention can also be performed on a microfluidic device, such as described in WO 2013/155553.
- An example of a BRET based assay performed on a microfluidics device (the CYBERTONGUE device) is provided in PCT/AU2018/050824.
- a microfluidic system for detecting an analyte in a sample comprising
- At least one reservoir suitable for containing an antibody or antibody-like molecule capable of binding to the analyte attached to a first component of a CRET pair
- a microfluidic device comprising one or more microchannels
- iv means for mixing the antibody or antibody-like molecule, the labelled antigen, the sample and a substrate of the first or second component of the CRET pair in the device,
- the efficiency of energy transfer between the first component of the CRET pair and the second component of the CRET pair is in the range of 10 to 75%;
- the system can be used to detect the analyte in real time.
- the antibody or antibody-like molecule is not fixed to the device.
- the antibody or antibody-like molecule, labelled antigen and substrate enter the device through different microchannels.
- the microfluidic device comprises at least two input microchannels, wherein one of the input microchannels is for flowing the antibody or antibody-like molecule into the device.
- the electro-optical sensing device comprises at least two different wavelength channels. In some examples, the electro-optical sensing device is capable of simultaneously, or in rapid succession, detecting two different wavelength channels. In some examples, the electro-optical sensing device is capable of detecting two different wavelength channels in less than 1 second.
- the microfluidic device is designed to enable the detection of two or more analytes.
- a labelled antigen comprising an antigen capable of binding to the antibody or antibody-like molecule attached to a second component of a CRET pair, c) a substrate of one of the first or second component of the CRET pair, wherein, when the labelled antigen is bound to the antibody or antibody-like molecule, the efficiency of energy transfer between the first component and the second component is in the range of 10 to 75%,
- step (i) comprises:
- the method comprises two or more different antibody or antibody-like molecules each of which binds a different analyte or range of analytes and two or more different labelled antigens.
- the methods can be used to classify samples in real time.
- the antibody or antibody like molecule is not fixed to the device.
- the antibody or antibody-like molecule, labelled antigen and substrate enter the device through different microchannels.
- the microfluidic device comprises at least two input microchannels, wherein one of the input microchannels is for flowing the antibody or antibody-like molecule into the device.
- the methods of classifying a sample can be used to classify as sample based on the presence or absence of one or more analytes or the concentration of an analyte.
- the methods may be used to classify a sample as free of an allergen when the allergen is present below a pre-determined level and/or is undetectable.
- a DNA sequence encoding amino acid residues 2 to 239 of GFP 2 was amplified by PCR. This was ligated into a modified pET43a E. coli expression vector designed to encode an N-terminal hexahistidine (His) tag followed by a tobacco etch virus protease (TEV) cleavage site, a SUMO solubility tag, SUMO protease cleavage site and a FLAG epitope, followed by the GFP 2 sequence.
- the resulting protein sequence is listed under SEQ ID NO: 4.
- Protein Expression To produce recombinant His-TEV-SUMO-FLAG-GFP 2 protein, the expression plasmid was transformed into E. coli BL21 DE3 strain and grown with shaking at 37 °C in Terrific broth (TB) supplemented with 100 pg/ml Ampicillin until an OD600 of 0.7 was reached. Cultures were transferred to 16 °C, protein expression was induced by the addition of isopropyl b-D-l- thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and the cultures were shaken overnight for a further 16 h. Following expression, cell cultures were centrifuged at 5000 x g for 20 min and the resulting cell pellets were stored frozen at - 20 °C.
- IPTG isopropyl b-D-l- thiogalactopyranoside
- Protein Purification was initiated by thawing the cell pellet in Lysis buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCh, 10 mM imidazole, 0.5 mg/ml lysozyme, 5 U/ml benzonase endonuclease [EMD Millipore], 1 mM PMSF, complete protease inhibitor tablets EDTA-free [Roche]) using a ratio of 5 ml of buffer per 1 g of cells. Cells were further lysed by 3 passes through an ice cooled Avestin C5 cell crusher and centrifuged at 48,000 x g at 4 °C.
- Lysis buffer 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCh, 10 mM imidazole, 0.5 mg/ml lysozyme, 5 U/ml benzonase endonuclease [
- IMAC column was sequentially washed with IMAC Wash buffer 1 and IMAC Wash buffer 2 (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole) and the bound His-TEV-SUMO-FLAG-GFP 2 protein eluted with IMAC Elution buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 350 mM imidazole).
- IMAC-eluted protein was further purified by passing through a HiLoad 16/60 Superdex 75 column (GE Healthcare) pre-equilibrated with gel filtration buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl).
- the purified His-TEV-SUMO-FLAG-GFP 2 protein was incubated with SUMO protease overnight at 16 °C and at a protein to protease ratio of 50:1 to remove the N-terminal His and SUMO tags. The next morning, imidazole was added to the reaction to a final concentration of 20 mM, and the reaction mixture was passed once more over a 5 ml HiTrap IMAC column to remove the protease and the cleaved tags. Two washes with IMAC Wash buffer 2 followed, and the untagged FLAG-GFP 2 protein was collected from the unbound fraction and the first IMAC wash.
- the fractions containing the cleaved FLAG-GFP 2 protein were then concentrated using Amicon Ultra centrifugal filter unit (Ultra- 15 MWCO lOkDa) and loaded onto a HiLoad 16/60 Superdex 75 column (GE Healthcare) pre-equilibrated with gel filtration buffer. The appropriate peak was collected and the protein was concentrated to 1.7 mg/ml before being flash-frozen in liquid nitrogen in 500 pi aliquots and stored at -70 °C. The presence of the FLAG epitope in all the fusion proteins was confirmed by Western blot analysis (data not shown).
- N-His-RLuc8 protein To produce recombinant N-His-RLuc8 protein, the expression plasmid was transformed into E. coli BL21 DE3 strain and grown with shaking at 37°C in Terrific broth (TB) supplemented with 100 pg/mL Ampicillin until an OD600 of 0.7 was reached. Cultures were transferred to 16 °C and protein expression was induced by the addition of IPTG to a final concentration of 0.5 mM. After the addition of IPTG, the cultures were shaken overnight for a further 16 hours. Following expression, cell cultures were centrifuged at 5000 x g for 20 min and cell pellets were stored frozen at -20 °C.
- TB Terrific broth
- Protein Purification was initiated by thawing the cell pellet in Lysis buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCh, 10 mM Imidazole, 0.5 mg/mL lysozyme, 5 U/mL benzonase endonuclease [EMD Millipore], 1 mM PMSF, complete protease inhibitor tablets EDTA-free [Roche]) using a ratio of 5 mL of buffer per 1 g of cells. Cells were further lysed by 3 passes through an ice cooled Avestin C5 cell crusher and centrifuged at 48,000 x g at 4 °C.
- Lysis buffer 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCh, 10 mM Imidazole, 0.5 mg/mL lysozyme, 5 U/mL benzonase endonuclease [
- IMAC column was then sequentially washed with IMAC Wash buffer 1 and IMAC Wash buffer 2 (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM Imidazole) then the bound N-terminal HIS tagged RLuc8 protein was eluted with IMAC Elution buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 350 mM Imidazole).
- the IMAC eluted protein was further purified by passing it through a Hi Load 16/60 Superdex 75 column pre-equilibrated in 1 x PBS (137 mM NaCl, 2.7 mM KC1, 4.3 mM NaiHPCC, 1.47 mM KH2PO4 pH 7.4). Fractions containing the monomer and dimer were pooled separately before being flash-frozen in 500 pL aliquots and stored at -70 °C.
- fractions contain RLuc8 were identified by SDS- PAGE analysis and Western blot analysis using an anti-His antibody-HRP conjugate and detection by a-chloronaphthol.
- Mass spectrometry analysis of the final pooled fractions found the mass of the protein to be 38981.2 Da, in excellent agreement with the predicted mass of 38981.37 Da (with loss of N-terminal methionine).
- Luciferase activity Coelenterazine 400a (Cayman Chemicals) (6-phenyl-2,8- /Asfphcnyl methyl )-imida/o[ 1 ,2-aJpyrazin-3(7H -onc) (1 mg) was dissolved in 10.2 mL ethanol and partitioned into 200 pL aliquots which were dried (Speedivac) and stored at - 20 °C until use.
- Coelenterazine 400a (50 nmol) was dissolved in 50 pL ethanol and 450 pL water was added.
- RLuc8 monomer (2.4 mg/mL) and RLuc8 dimer (4.8 mg/mL) were dilulted in 1 mg/mL BSA in buffer.
- TBS TBS
- PBS PBS or 100 mM sodium phosphate pH 7.0
- 2 pL luciferase enzyme (1/10 or 1/100 dilution)
- 5 pL of 0.1 mM Coelenterazine 400a solution was 100 pL.
- Protein Purification was initiated by thawing the cell pellet in Lysis buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgC12, 10 mM Imidazole, 0.5 mg/mL lysozyme, 5 U/mL benzonase endonuclease [EMD Millipore], 1 mM PMSF, complete protease inhibitor tablets EDTA-free [Roche]) using a ratio of 5 mL of buffer per 1 g of cells. Cells were further lysed by 3 passes through an ice cooled Avestin C5 cell crusher and centrifuged at 48,000 x g at 4 °C.
- Lysis buffer 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgC12, 10 mM Imidazole, 0.5 mg/mL lysozyme, 5 U/mL benzonase endonucleas
- IMAC column was sequentially washed with IMAC Wash buffer 1 and IMAC Wash buffer 2 (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM Imidazole) and bound HIS-TEV-SUMO-FLAG-RLuc8 protein eluted with IMAC Elution buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 350 mM Imidazole).
- the IMAC-eluted protein was further purified by passing it through a HiLoad 16/60 Superdex 75 column pre-equilibrated in 1 x PBS (137 ruM NaCl, 2.7 mM KC1, 4.3 ruM Na2HP04, 1.47 mM KH2P04 pH 7.4).
- the purified protein was incubated with SUMO protease overnight, at 16 °C, at a protein to protease ratio of 20: 1 to remove the N-terminal HIS and SUMO tags.
- imidazole was added to the reaction to a final concentration of 20 mM and the reaction mixture was passed once more over a 1 mL HiTrap IMAC column to remove the protease and the cleaved tags.
- Cleaved FLAG-RLuc8 proteins were concentrated using an Amicon Ultra centrifugal filter unit (Ultra- 15 MWCO lOkDa) and loaded onto a HiLoad 16/60 Superdex 200 column pre-equilibrated in 1 x PBS (137 mM NaCl, 2.7 mM KC1, 4.3 mM Na2HP04, 1.47 mM KH2P04 pH 7.4). The monomer and dimer were collected separately and protein concentrated to > 1.2 mg/mL. The protein was flash-frozen in liquid nitrogen in 100 pL aliquots and stored at -70 °C.
- fractions contain RLuc8 were identified by SDS- PAGE analysis and/or Western blot analysis using an anti-His antibody-HRP conjugate and detection by a-chloronaphthol.
- Anti-FLAG antibody was produced from the anti-FLAG M2 hybridoma (Brizzard et al., 1994) and purified on Ab-Capcher resin (Cosmo Bio). Anti-FLAG (8 mL, 3.5 mg/mL) was desalted to PBS adjusted to pH 6.4 on a HiPrep desalting column (GE Healthcare). Uncut anti-FLAG antibody was isolated by gel filtration (data not shown).
- cleavage reactions were set up with 20 pg anti-FLAG antibody and papain added at enzyme/antibody ratios of 1:5 to 1:2560.
- the reaction mixture was incubated at 37 °C overnight, in the presence of 0 or 10 mM cysteine, before 5 pL 0.5 M iodoacetamide was added to the reaction mixture to quench the reaction. The extent of the cleavage was then assessed by SDS-PAGE.
- Fab’2 was isolated by gel filtration on a HiLoad 26/60 Superdex 200 column (GE Healthcare) equilibrated with PBS. The purity of the isolated Fab’2 was then assessed by SDS- PAGE.
- Anti-FLAG antibody was treated with tris(2-carboxyethyl)phosphine (TCEP) (final concentration 50 pM) for 4 h at 25 °C before being desalted into PBS using NAP G-25 desalting columns (GE Healthcare). The reduced antibody was used without further purification in the subsequent conjugation reactions.
- TCEP tris(2-carboxyethyl)phosphine
- Anti-FLAG Fab’ 2 was reduced with TCEP (final concentration 100 pM) for 2 h at 25 °C before being diluted with MES buffer (20 mM, pH 6) and applied to a HiTrap SP HP cation exchange column (1 mL, GE Healthcare) equilibrated with the same buffer. The column was washed with Buffer A (PBS) and the bound protein was eluted with a linear gradient from 0 - 100% Buffer B (PBS to which 0.85 M NaCl has been added).
- PBS Buffer A
- DHAA dehydroascorbic acid
- hydrazinonicotinamide-antiFLAG antibody derivative Reduced anti-FLAG antibody (16.4 nmol) in PBS (700 pL) was treated with 164 nmol MHPH (Maleimide HyNic, maleimidyl-6-hydrazine-nicotinamide, TriLink Biotechnologies; 3.29 pi of 50 mM MHPH in anhydrous DMSO)) and the mixture was allowed to react for 90 minutes at room temperature. Excess MHPH was removed by desalting on a HiTrap desalting column into PBS. A small aliquot of the hydrazinonicotinamide-derivatised anti-FLAG antibody was subjected to mass spectrometric analysis.
- Derivatisation of reduced anti-FLAG antibody with hydrazinonicotinamide could be inferred from mass spectrometry analysis.
- Mass spectrum of non-derivatised reduced antibody showed peaks at 24110.8 Da (light chain) and multiple peaks at 50282.8 Da and higher (heavy chain, variation in glycosylation).
- Mass spectrum of hydrazinonicotinamide-derivatised antibody showed a small peak at 50475.6 Da (heavy chain + 192.8 Da), corresponding to the addition of hydrazinonicotinamide (expected MW + 191.0 Da), suggesting that conjugation had occurred.
- hydrazinonicotinamide-Fab’ derivative Preparation of hydrazinonicotinamide-Fab’ derivative: Anti-FLAG Fab’ (7.2 nmol) in PBS (600 pL) was treated with 72 nmol MHPH (1.44 m ⁇ of 50 mM MHPH in anhydrous DMSO) and the mixture was allowed to react for 90 minutes at room temperature. Excess linker was removed by desalting on a HiTrap desalting column into PBS. A small aliquot of the hydrazinonicotinamide-derivatised anti-FLAG Fab’ was subjected to mass spectrometric analysis.
- the remaining reaction mixture was buffer exchanged to 20 mM MES, 150 mM NaCl pH 6.0 using an Amicon 10 kDa MWCO spin concentrator (Merck Millipore). Aniline was added to a final concentration of 10 mM and one portion left at 4 °C and the second portion at room temperature for 16 h before being subjected to gel filtration purification as above.
- the gel filtration profile for both reactions were very similar to the profile observed for reaction in PBS.
- the hydrazinonicotinamide: formylbenzamide bonds absorbs at 354 nm with a molar extinction coefficient of 29000 (TriLink product literature), however the absorbance of the conjugate was too low to allow an estimation of the concentration using the absorbance at 354 nm.
- RLuc8-antiFab’ conjugate One-third of the formylbenzamide-derivatised RLuc8RLuc8 was added to hydrazinonicotinamide - derivatised anti-FLAG Fab’ 2. Aniline was added to a final concentration of 10 mM and the conjugation reaction was allowed to proceed at 4 °C for about 54 h before a portion (400 pL) was purified by gel filtration on a Superdex 200 10/300 Increase gel filtration column (GE Healthcare) equilibrated with PBS.
- the elution profile of the conjugation reaction mixture showed a new peak of protein eluting at 14.5 mL, earlier than either RLuc8 (elution peak at -16.5 mL) and Fab’ (elution peak also at -16.5 mL).
- the remaining reaction mixture was concentrated and buffer exchanged to 20 mM MES, 150 mM NaCl pH 6.0 using an Amicon 10 kDa MWCO spin concentrator (Merck Millipore). Aniline was added to a final concentration of 10 mM and one portion left at 4 °C and the second portion at room temperature for 16 h before being subjected to gel filtration purification as above.
- the gel filtration profile for both reactions were very similar to the profile observed for reaction in PBS.
- the peak corresponding to conjugated protein was collected
- the hydrazinonicotinamide: formylbenzamide bond absorbs at 354 nm with a molar extinction coefficient of 29000 (TriLink product literature).
- the concentration of the hydrazinonicotinamide: formylbenzamide bond in the final pool was estimated to be 50 nM (as determined by integration of the chromatogram at 354 nm).
- Example 7 Conjugation of RLuc8 to anti-FLAG antibody and anti-FLAG Fab’ via a PEG linker using Click chemistry
- azido-PEG n -RLuc8 derivative N-His-RLuc8 (25 nmol in 240 pL PBS)) was reacted with azido-dPEG ® 8-NHS ester (125 nmol) (Quanta Biodesign) for 90 minutes at room temperature. Excess azido-dPEG ® 8-NHS ester was removed by desalting on a HiTrap desalting column into PBS. The resulting azido-PEG8- derivatised protein was used without further purification in the subsequent conjugation reactions. A small aliquot of the material was analysed by mass spectrometry.
- DBCO-PEG m -antiFLAG antibody derivative Partially reduced anti-FLAG antibody (16.4 nmol) in PBS (700 L) was treated with DBCO- dPEG ® 4-Mal (Quanta Biodesign) (164 nmol; 3.29 pi of 50 mM DBCO-dPEG ® 4-Mal in anhydrous DMSO) and the mixture was allowed to react for 90 min at 25 °C. Excess DBCO-dPEG ® 4-Mal was removed by desalting into PBS using a HiTrap column. A small aliquot of the resulting protein was subjected to analysis by mass spectrometry.
- DBCO-PEG m -Fab’ derivative Partially reduced anti-FLAG Fab’2 (7.2 nmol) in PBS (600 qL) was treated with DBC0-dPEG ® 4-Mal (72 nmol; 1.44 qL of 50 mM DBCO-dPEG ® 4-Mal in anhydrous DMSO) and the mixture was allowed to react for 90 min at 25 °C. Excess DBCO-dPEG ® 4-Mal was removed by desalting into PBS using a HiTrap column. A small aliquot of the resulting protein was subjected to analysis by mass spectrometry.
- the antibody:RLuc8 and Fab’:RLuc8 conjugates comprising the Solulink and Click- PEG linkers, were tested to determine the efficiency of energy transfer between the BRET components RLuc8, free or conjugated to antibody or Fab’, and GFP 2 , conjugated to FLAG peptide.
- FLAG peptide (DYKDDDDK; SEQ ID NO: 7)) was obtained from Peptide 2.0 Inc, US.
- RLuc8 or RLuc8 conjugate with or without FLAG- GFP 2 and FLAG peptide (various concentrations) were made up to a final volume of 95 pL with PBS and incubated for 5 minutes. After incubation, 5 pL of 0.1 mM Coelenterazine 400a (Cayman Chemicals) in ethanol (0.5 nmol) was added and the luminescence/ fluorescence was determined.
- BRET transfer was analysed using a FLUOstar Optima fluorimeter (BMG Labtech) with simultaneous dual emission optics equipped with a 410 nm emission filter in the first position and a 515 nm filter in the second position.
- Luminescence/ fluorescence was determined.
- BRET transfer was analysed using a FLUOstar Optima fluorimeter (BMG Labtech) with simultaneous dual emission optics equipped with a 410 nm emission filter in the first position and a 515 nm filter in the second position. An integration time of 0.5s was used for measurements.
- the BRET ratio is defined as the ratio of light intensity at 520 nm to that at 420 nm. BRET ratio was calculated by dividing the GFP 2 intensity (average 0 - 5 s) by the RLuc8 intensity (average 0 - 5 s).
- the partially reduced anti-FLAG antibody (84 nmol in 3 mL PBS) or Fab’ (16 nmol in 3 mL PBS) were reacted with 2 equivalents of DBCO-dPEG4-Mal, DBCO- dPEG12-Mal or DBCO-dPEG24-Mal (Quanta Biodesign) at 4 °C for 64 h without mixing, before the protein and conjugate were separated from the excess low MW Click reagent by gel filtration on a Superdex S200 16/60 column (GE Healthcare) equilibrated with PBS.
- Conjugation reactions were set up between the azido-PEG n -derivatised RLuc8 and approximately equimolar amounts of the DBCO-PEG m -derivatised antibody, or 0.25 - 0.4 molar equivalents of the DBCO-PEG m -derivatised Fab’ due its limited availability.
- the reactions were incubated at 4 °C for 40 h before being analysed by SDS-PAGE. As the a large amount of starting material remained unreacted, the reaction mixtures were concentrated and left to proceed for a further week before the conjugates were isolated by gel filtration then analysed by SDS-PAGE. SDS-PAGE analysis indicated that conjugation occurred only at the heavy chains (data not shown). The concentration of the purified conjugate was estimated spectroscopically.
- the purified conjugates were used in the BRET assays described in Example 8.
- BRET transfer was determined as previously except a solution of 1 mM Coelenterazine 400a in 50 pL ethanol was prepared, with 0.5 pL being added to the final assay.
- the BRET ratio was determined using 50 nM antibody- or Fab’-RLuc8 conjugate, 100 or 200 nM FLAG-GFP 2 and FLAG peptide, as appropriate.
- the reaction mixture was made up to volume with PBS.
- the final reaction volume after the addition of Coelenterazine 400a was 100 pL.
- the BRET assays were performed as described in Example 8 except a solution of 1 mM coelenterazine 400a was prepared in 50 pL of ethanol, with 0.5 pL being added to the final assay.
- BRET ratio was determined for each of the antibody-Click/PEG-RLuc8 conjugates alone (50 nM) or with 100 or 200 nM FLAG-GFP 2 , or with 200 nM FLAG-GFP 2 and 1 pM FLAG peptide.
- the BRET ratio for the antibody-Click/PEG-RLuc8 conjugates increased from 0.05 in the absence of FLAG-GFP 2 to approximately 0.2 in the presence of 100 nM FLAG-GFP 2 , further increasing to 0.25 in the presence of 200 nM FLAG-GFP 2 ( Figure 4A). In the presence of 1 pM FLAG peptide, the ratio dropped to approximately half, indicating the FLAG peptide was able to compete for the antibody:RLuc8 conjugate with FLAG-GFP 2 .
- the antibody- 12/36- RLuc8 conjugate was incubated with 200 nM FLAG-GFP 2 and varying concentrations of FLAG peptide (from 256 mM to less than 0.5 nM) for 5 minutes before coelenterazine 400a was added and the BRET ratio determined using the Fluorostar plate-reader as described in Example 9. The BRET ratios were plotted against Log [FLAG] values.
- a calibration was also performed using the Clariostar plate -reader (BMG) and the antibody-24/36-RLuc8 conjugate. Measurements were made in the bioluminescence mode and the dual linear variable filters were set to 410-80 (Gain: 3300) for RLuc8 emission and 515-30 (Gain: 4095) for GFP 2 emission. An integration time of 1.54 s was used.
- Coelenterazine 400a was prepared by adding 100 pL ethanol to a dried aliquot (0.5 mM), with 1 pL added to the final assay to give a final concentration of 5 pM. A final concentration of 5 nM of RLuc8-conjugate and 10 nM GFP 2 -FLAG was used for assays. The final assay volume was 100 pL with PBS (with BSA (1 mg/ml) used to make up the volume.
- the BRET ratio was dependent on the concentration of the FLAG peptide. This suggests that the antibody- 12/36-RLuc8, in the presence of FLAG-GFP 2 can be used to determine the amount of FLAG peptide in a sample. The point of inflection in the curve approximately corresponds to the Kd for the antibody :FLAG interaction (180 nM, Hong et al., 2011).
- the calibration curve determined using the Clariostar plate-reader with the antibody 24/36-RLuc8 conjugate is shown in Figure 6.
- the EC50 was calculated to be 1.41 nM of FLAG peptide.
- the response was linear between 5.41 pM (90 %) and 0.37 mM (10 %) with a detection limit of 4.16 pM (Blank ⁇ SD *3) with a 5 minute incubation.
- the detection limit for a BRET assay based on the Firefly/Cy3.5 BRET system was 0.2 pM (Yamakawa et al., 2002) and the detection limit for a BRET assay based on the GreenLuc/AF610 BRET system was 1.7 nM (Smirnova et al., 2016). This is summarised in Table 4.
- Fractions at 17 mins were combined and reduced to dryness in vacuo.
- Combined fractions (8 mg, 68.8 % yield) were analysed by analytical FC-MS ((Waters Alliance aHPFC, C18 reverse phase, to QDa mass detector) gradient elution 0-80% B, detect at 214 nm).
- FLAG-GFP 2 (Example 1) was desalted to PBS. 20, 30 or 40 nmol DBCO-dPEG4-TFP ester (Quanta Biodesign) was added to 20 nmol protein and the mixture allowed to react at 4 °C overnight. The reaction mixtures were analysed by mass spectrometry and then pooled. A large excess (1.9 pmol) of ampicillin-PEG8-N 3 was added to 56 nmol GFP 2 -PEG4-DBCO reaction mixture. The reaction was allowed to proceed at 4 °C overnight before being purified by gel filtration and the protein pools analysed by mass spectrometry.
- N-His-T9-NBl-RFuc8 protein was transformed into E. coli BF21 DE3 strain and grown with shaking at 37°C in 1 F volumes of TB supplemented with 100 pg/ml Ampicillin until an OD600 of 0.7 was reached. Cultures were transferred to 16°C and protein expression induced by the addition of IPTG to a final concentration of 0.5 mM and the cultures incubated with shaking for further 16 hours. Following expression, cell cultures were centrifuged at 5000 x g for 20 min and the cell pellet stored frozen at - 20°C.
- Protein Purification was initiated by thawing the cell pellet in Lysis buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCh, 10 mM Imidazole, 0.5 mg/ml lysozyme, benzonase endonuclease [EMD Millipore], 1 mM PMSF, complete protease inhibitor tablets EDTA-free [Roche]) using a ratio of 5 ml of buffer per 1 g of cells. Cells were further lysed by 3 passes through an ice cooled Avestin C5 cell crusher and then centrifuged at 48,000 x g at 4°C.
- Lysis buffer 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCh, 10 mM Imidazole, 0.5 mg/ml lysozyme, benzonase endonuclease [EMD Millipore], 1 mM
- Supernatant (cell lysate) was filtered through a 5 pm filter and applied to 1 ml HiTrap IMAC Sepharose FF column (GE Healthcare) pre-equilibrated with IMAC wash buffer 1 (25 mM Tris- HCl pH 8.0, 300 mM NaCl, 10 mM Imidazole) using Profinia Affinity chromatography purification system (Bio-Rad). The IMAC column was then sequentially washed with IMAC Wash buffer 1 and IMAC Wash buffer 2 (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM Imidazole). After washing, bound protein eluted with IMAC Elution buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 350 mM Imidazole).
- the eluted protein was incubated overnight at 4°C with TEV protease at a protein to protease molar ratio of 20: 1 in a Spectra/Por dialysis membrane (MWCO 3500Da) while dialysing against IMAC Wash buffer 2 supplemented with
- the dialysed digestion reaction was then passed over a 1 ml HiTrap IMAC Sepharose FF column to capture the his tagged TEV protease and the cleaved hexahistidine tag. The column was subsequently washed twice with IMAC Wash buffer
- TCC-4'-S-(CH 2 ) 2 -CO-GFP 2 TCC-4'-S-(CH 2 ) 2 -CC> 2 H (2 mg) was dissolved in a mixture of PBS (pH 7.4, 700 pL) and 135 pL DMSO. This solution was then added, at room temperature, to a solution of FLAG-GFP 2 in PBS (pH 7.4, 1.40 mg/mL, 1.25 mL, 1.75 mg).
- EDC (10 mg) was dissolved in 1 mL PBS (pH 7.4) and sulfo-NHS (10 mg) was dissolved in 1 mL PBS (pH 7.4).
- TCC-4'-S-(CH 2 ) 2 -CO-GFP 2 conjugate was purified by use of a PD- 10 column following the GE Healthcare protocol to yield 3.5 mL of TCC-4'-S- (CH 2 )2-CO-GFP 2 conjugate at 2.84 mg/mL.
- Example 14 Detection of a small molecule using a BRET sensor
- the methods and immunosensors described herein can be used to detect a small molecule, such as TCC.
- Figure 7 shows the schematic competitive assay where addition of a small molecule to an exemplified immunosensor described herein results in a decrease in BRET ratio due to competitive binding of the unlabelled, antigen to the nanobody in the place of the labelled antigen.
- BRET 2 measurements were carried out with a CLARIOstar microplate reader (BMG LabTech).
- BRET 2 measurements used the BRET 2 emission filter set comprising RLuc/CLZ400a emission filter (410 nm bandpass, 80 nm) and the GFP 2 emission filter (515 nm bandpass, 30 nm).
- BRET 2 ratios were calculated as ratios of integrated acceptor emission channel intensity to integrated donor emission channel intensity.
- BRET 2 assay All reactions were carried out in white 96- well plates (Perkin- Elmer, Australia). A final concentration of 10 nM of T9NBl-RLuc8 and 10 nM of TCC-4'-S-(CH 2 ) 2 -CO-GFP 2 were used for all assays, in a final volume of 100 pL 2% DMSO in PBS.
- a final concentration of 10 nM T9NBl-RLuc8 only, 10 nM T9NBl-RLuc8 with 10 nM of TCC-4'-S-(CH 2 ) 2 -CO-GFP 2 or 10 nM T9NBl-RLuc8 with 10 nM GFP 2 were used for control assays, in a final volume of 100 pL 2% DMSO in PBS.
- the purified proteins were incubated for 5 minutes at 22°C.
- the BRET 2 ratios were calculated and are shown in Figure 9.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Plasma & Fusion (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Clinical Laboratory Science (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020265898A AU2020265898A1 (en) | 2019-05-01 | 2020-04-30 | Immunosensor |
CN202080047293.2A CN114341637A (en) | 2019-05-01 | 2020-04-30 | Immunosensor |
EP20798406.3A EP3963324A4 (en) | 2019-05-01 | 2020-04-30 | Immunosensor |
JP2021564555A JP2022531246A (en) | 2019-05-01 | 2020-04-30 | Immune sensor |
US17/594,837 US20220268706A1 (en) | 2019-05-01 | 2020-04-30 | Immunosensor |
KR1020217039177A KR20220034034A (en) | 2019-05-01 | 2020-04-30 | immune sensor |
CA3138608A CA3138608A1 (en) | 2019-05-01 | 2020-04-30 | Immunosensor |
ZA2021/09785A ZA202109785B (en) | 2019-05-01 | 2021-11-30 | Immunosensor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019901483A AU2019901483A0 (en) | 2019-05-01 | Immunosensor | |
AU2019901483 | 2019-05-01 | ||
AU2019901566A AU2019901566A0 (en) | 2019-05-08 | Immunosensor | |
AU2019901566 | 2019-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020220086A1 true WO2020220086A1 (en) | 2020-11-05 |
Family
ID=73029225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2020/050430 WO2020220086A1 (en) | 2019-05-01 | 2020-04-30 | Immunosensor |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220268706A1 (en) |
EP (1) | EP3963324A4 (en) |
JP (1) | JP2022531246A (en) |
KR (1) | KR20220034034A (en) |
CN (1) | CN114341637A (en) |
AU (1) | AU2020265898A1 (en) |
CA (1) | CA3138608A1 (en) |
WO (1) | WO2020220086A1 (en) |
ZA (1) | ZA202109785B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024070697A1 (en) * | 2022-09-26 | 2024-04-04 | 富士フイルム株式会社 | Immunochromatography testing device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013155553A1 (en) * | 2012-04-16 | 2013-10-24 | Commonwealth Scientific And Industrial Research Organisation | Methods and systems for detecting an analyte or classifying a sample |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
WO2016139643A2 (en) * | 2015-03-04 | 2016-09-09 | University College Dublin, National University Of Ireland, Dublin | Molecular sensors |
US10138267B2 (en) * | 2015-04-06 | 2018-11-27 | Hunan Skyworld Biotechnologies Co. Ltd. | Bioconjugates of heterocyclic compounds |
US11740238B2 (en) * | 2015-09-04 | 2023-08-29 | Pioneer Hi-Bred International, Inc. | Compositions and methods of detecting a substance of interest |
-
2020
- 2020-04-30 EP EP20798406.3A patent/EP3963324A4/en active Pending
- 2020-04-30 WO PCT/AU2020/050430 patent/WO2020220086A1/en unknown
- 2020-04-30 AU AU2020265898A patent/AU2020265898A1/en active Pending
- 2020-04-30 CA CA3138608A patent/CA3138608A1/en active Pending
- 2020-04-30 JP JP2021564555A patent/JP2022531246A/en active Pending
- 2020-04-30 CN CN202080047293.2A patent/CN114341637A/en active Pending
- 2020-04-30 KR KR1020217039177A patent/KR20220034034A/en unknown
- 2020-04-30 US US17/594,837 patent/US20220268706A1/en active Pending
-
2021
- 2021-11-30 ZA ZA2021/09785A patent/ZA202109785B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013155553A1 (en) * | 2012-04-16 | 2013-10-24 | Commonwealth Scientific And Industrial Research Organisation | Methods and systems for detecting an analyte or classifying a sample |
Non-Patent Citations (10)
Title |
---|
DACRES, HELEN, MICHIE MICHELLE, WANG JIAN, PFLEGER KEVIN D.G., TROWELL STEPHEN C.: "Effect of enhanced Renilla luciferase and fluorescent protein variants on the Forster distance of Bioluminescence resonance energy transfer (BRET", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 425, 2012, pages 625 - 629, XP055758255, DOI: 10.1016/j.bbrc.2012.07.133 * |
DE , A. ET AL.: "Engineering Aspects of Bioluminescence Resonance Energy Transfer Systems", ENGINEERING IN TRANSLATIONAL MEDICINE, 2014, pages 257 - 300, XP055758251 * |
GAO, H. ET AL.: "Amorphous carbon nanoparticle used as novel resonance energy transfer acceptor for chemiluminescent immunoassay of transferrin", ANALYTICA CHIMICA ACTA, vol. 819, 2014, pages 102 - 107, XP028631232, DOI: 10.1016/j.aca.2014.02.018 * |
HEPOJOKI, S. ET AL.: "Competitive Homogenous Immunoassay for Rapid Serodiagnosis of Hantavirus Disease", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 53, no. 7, 2015, pages 2292 - 2297, XP055515962, DOI: 10.1128/JCM.00663-15 * |
LE, NAM CAO HOAI, GEL MURAT, DACRES HELEN, ANDERSON ALISHA, TROWELL STEPHEN C.: "Sub-nanomolar detection of thrombin activity on a microfluidic chip", BIOMICROFLUIDICS, vol. 8, 2014, pages 1 - 11, XP055758244, DOI: 10.1063/1.4902908 * |
See also references of EP3963324A4 * |
TAKKINEN, K. ET AL.: "Recent advances in homogenous immunoassays based on resonance energy transfer", CURRENT OPINION IN BIOTECHNOLOGY, vol. 55, 2019, pages 16 - 22, XP085596462, DOI: 10.1016/j.copbio.2018.07.003 * |
WU, N. ET AL.: "Comparison of Static and Microfluidic Protease Assays using modified Bioluminescence Resonance Energy Transfer Chemistry", PLOS ONE, vol. 9, no. 2, 2014, pages e88399, XP055633149, DOI: 10.1371/journal.pone.0088399 * |
XUE, L. ET AL.: "Bioluminescent Antibodies for Point-of-Care Diagnostics", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 56, 2017, pages 7112 - 7116, XP055527910, DOI: 10.1002/anie.201702403 * |
YU , XUEZHI, WEN KAI, WANG ZHANHUI, ZHANG XIYA, LI CHENGLONG, ZHANG SUXIA, SHEN JIANZHONG: "General Bioluminescence Resonance Energy Transfer Homogenous Immunoassay for Small Molecules Based on Quantum Dots", ANALYTICAL CHEMISTRY, vol. 88, no. 7, 2016, pages 3512 - 3520, XP055757529, DOI: 10.1021/acs.analchem.5b03581 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022531246A (en) | 2022-07-06 |
CA3138608A1 (en) | 2020-11-05 |
CN114341637A (en) | 2022-04-12 |
AU2020265898A1 (en) | 2021-12-23 |
EP3963324A1 (en) | 2022-03-09 |
ZA202109785B (en) | 2023-06-28 |
KR20220034034A (en) | 2022-03-17 |
EP3963324A4 (en) | 2023-07-05 |
US20220268706A1 (en) | 2022-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Su et al. | Fluonanobody-based nanosensor via fluorescence resonance energy transfer for ultrasensitive detection of ochratoxin A | |
Wang et al. | Recent progress in strategies for the creation of protein‐based fluorescent biosensors | |
EP3538665B1 (en) | Protease sensor molecules | |
CN104871001A (en) | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer | |
JP2008516607A (en) | Development of high sensitivity FRET sensor and its use | |
EP3665481B1 (en) | Carbohydrate sensors | |
CA2602972A1 (en) | Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret) | |
Xie et al. | Nanobody/NanoBiT system-mediated bioluminescence immunosensor for one-step homogeneous detection of trace ochratoxin A in food | |
US20120269734A1 (en) | Self-Illuminating Dot Systems and Methods of Use Thereof | |
Dacres et al. | Comparison of enhanced bioluminescence energy transfer donors for protease biosensors | |
Cevenini et al. | Luciferase genes as reporter reactions: how to use them in molecular biology? | |
US20220268706A1 (en) | Immunosensor | |
Ge et al. | Combinational biosynthesis of dual-functional streptavidin-phycobiliproteins for high-throughput-compatible immunoassay | |
Niu et al. | Novel fluorescence-based biosensors incorporating unnatural amino acids | |
Nhat et al. | Antibody-based fluorescent and fluorescent ratiometric indicators for detection of phosphotyrosine | |
Gorokhovatsky et al. | Homogeneous assay for biotin based on Aequorea victoria bioluminescence resonance energy transfer system | |
A Frank | Creation of artificial luciferases to expand their analytical potential | |
US20080108128A1 (en) | Resonance Energy Transfer Assay System for Multi-Component Detection | |
Deo et al. | Bioluminescence resonance energy transfer from aequorin to a fluorophore: an artificial jellyfish for applications in multianalyte detection | |
US8569003B2 (en) | Fusion protein having luminescence activity | |
Pradanas-González et al. | Biosensing strategies using recombinant luminescent proteins and their use for food and environmental analysis | |
Bonomi et al. | Modern methods to investigate the oligomerization of glycoprotein hormone receptors (TSHR, LHR, FSHR) | |
US20220244248A1 (en) | Homogeneous immunoassay method using peptide having multiple fluorochromes joined thereto | |
Huang et al. | Improvement of the sensitivity of the detection of Gal d 6-specific IgE via biotinylation in vivo | |
Hamorksy | Genetically Engineered Aequorin for the Development of Novel Bioanalytical Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20798406 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021564555 Country of ref document: JP Kind code of ref document: A Ref document number: 3138608 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020798406 Country of ref document: EP Effective date: 20211201 |
|
ENP | Entry into the national phase |
Ref document number: 2020265898 Country of ref document: AU Date of ref document: 20200430 Kind code of ref document: A |